Document:

EX-10.13

 Exhibit 10.13 

EMPLOYMENT AGREEMENT 

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into between Vantage Drilling International (the “Company”) and
Ihab Toma (“Executive”) as of August 9, 2016, to be effective on August 29, 2016 (the “Effective Date”). 

R E C I T A L S: 

WHEREAS, Executive desires to be employed by the Company effective as of the Effective Date and the Company desires to employ Executive as an
integral part of the Company’s management as the Chief Executive Officer of the Company; and 
 WHEREAS, the Company desires to obtain
assurances from Executive that he will devote his best efforts to the Company and will not enter into competition with the Company, solicit its customers, or solicit employees of the Company after termination of his employment; and 

WHEREAS, Executive is expected to serve as a key employee with special and unique talents and skills of peculiar benefit and importance to the
Company; and 
 WHEREAS, Executive is desirous of committing himself to serve on the terms herein provided. 

NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the parties hereto agree to
this Agreement as follows: 
  

	1.	EMPLOYMENT TERM AND DUTIES 

 1.1 Term of Employment. Effective as of the
Effective Date, the Company hereby agrees to employ Executive as its Chief Executive Officer, and Executive hereby agrees to accept such employment, on the terms and conditions set forth herein, for the period commencing on the Effective Date and
expiring as of the second anniversary of the Effective Date (the “Basic Term”) (unless sooner terminated as hereinafter set forth). Unless sooner terminated as hereinafter set forth, the Basic Term shall be automatically extended by one
year commencing at the end of the Basic Term and on each subsequent one-year anniversary date thereafter (each such date being a “Renewal Date”), unless and until at least ninety (90) days prior to a Renewal Date either party hereto
gives written notice to the other that the Basic Term should not be further extended after the next Renewal Date (a “Notice of Non-Renewal”), in which event the Termination Date shall be the Renewal Date next following receipt of the
Notice of Non-Renewal. For the removal of any doubt, unless the Company provides Executive with written notice of its intention not to renew this Agreement at least ninety (90) days prior to the expiration of the Basic Term or before the
Renewal Date, this Agreement shall automatically renew for an additional one-year period. The period of time commencing on the Effective Date until the Agreement has been terminated as set forth herein shall be referred to as the “Employment
Period.” 

  
 1 

 1.2 Duties as Executive of the Company. Executive shall, subject to the supervision
of the Board of Directors of the Company (the “Board”), have general executive management and control of the Company in the ordinary course of its business with all such powers with respect to such management and control as may be
reasonably incident to such responsibilities. Executive shall devote his full time and attention to diligently attending to the business of the Company during the Employment Period. During the Employment Period, Executive shall not directly or
indirectly render any services of a business, commercial, or professional nature to any other person, firm, corporation, or organization, whether for compensation or otherwise, without the prior written consent of the Board. However, Executive shall
have the right to (i) serve on corporate, civic or charitable boards or committees, provided that the Board must approve in advance Executive’s service on any outside corporate board, (ii) deliver lectures or fulfill speaking
engagements at educational institutions, and (iii) engage in such activities as may be reasonably appropriate in order to manage his personal investments, so long as all activities set forth in the preceding clauses (i), (ii) and (iii), in
the aggregate, do not materially interfere or conflict with the performance of his duties to the Company hereunder. 
 1.3
Fiduciary Duty. Executive acknowledges and agrees that he owes a fiduciary duty to the Company and further agrees to make full disclosure to the Company of all business opportunities pertaining to the Company’s business. Executive
shall not act for his own benefit concerning the subject matter of his fiduciary relationship. 
 1.4 Compliance.
Executive agrees that he will not take any action in violation of United States laws or other laws applicable to Executive’s employment, including, but not limited to, the Foreign Corrupt Practices Act, the UK Bribery Act of 2010, and the
Securities Exchange Act of 1934 (the “Exchange Act”). 
  

	2.	COMPENSATION AND RELATED MATTERS 

 2.1 Base Salary. Executive shall receive
a base salary (the “Base Salary”) paid by the Company at the annual rate of $500,000 (Five Hundred Thousand Dollars), payable in accordance with the Company’s general payment practices, but no less frequently than monthly, in
substantially equal installments, with the opportunity for increases from time to time thereafter in accordance with the Company’s regular executive compensation practices, subject to approval by the Compensation Committee of the Board (the
“Compensation Committee”). 
 2.2 Annual Bonus. For each full fiscal year of the Company that begins and ends
during the Employment Period, Executive shall be eligible to earn an annual cash bonus in such amount as shall be determined by the Compensation Committee based on the achievement by the Company and/or Executive of performance goals established by
the Compensation Committee for each such fiscal year; provided that (i) the “Target Annual Bonus Opportunity” shall be equal to 100% of Executive’s Base Salary and (ii) Executive’s maximum annual bonus opportunity in
respect of any fiscal year shall be equal to 200% of Executive’s Base Salary, but with the actual bonus amount (if any) determined by the Compensation Committee based upon the achievement of the applicable performance goals. The Compensation
Committee shall establish criteria it deems appropriate to be used to determine the extent to which performance goals have been satisfied. Notwithstanding the foregoing, with respect to the Company’s 2016 fiscal year, Executive will be eligible
to receive a pro-rated portion (based on the number of days Executive was employed by the Company during the Company’s 2016 fiscal year) of the 2016 annual cash bonus, if any, that Executive would otherwise have earned for 2016, as determined
and paid as set forth above. 

  
 2 

 2.3 Expenses. During the Employment Period, Executive shall be entitled to receive
prompt reimbursement for all reasonable expenses (including, without limitation, business, travel and entertainment expenses) incurred by him in accordance with the policies and procedures established by the Compensation Committee for the
Company’s senior executive officers in performing services for the Company, provided that Executive properly accounts for such expenses in accordance with the Company’s policies and procedures. 

2.4 Housing Allowance. The Company shall provide Executive with a housing allowance of $7,500 per month during the Employment
Period. The foregoing housing allowance shall be payable on the Company’s first ordinary payroll date of each applicable calendar month during such period, provided, however, that (i) in no event shall any such payment be made after the
third anniversary of the Effective Date and (ii) such payments shall be payable only to the extent Executive remains employed by the Company as of the applicable payment date. 

2.5 Vacation. Executive shall be entitled to four (4) weeks of vacation per year (pro-rated for 2016 as required by
Section 2.9). Vacation not taken during the applicable fiscal year (but not in excess of three weeks) shall be carried over to the next following fiscal year, subject to the Company’s then current practices. 

2.6 Welfare, Pension and Other Retirement Benefit Plans. During the Employment Period, Executive (and his eligible spouse and
dependents) shall be entitled to participate in all the welfare benefit plans and programs maintained by the Company from time-to-time for the benefit of its senior executives generally, including, without limitation, all medical, hospitalization,
dental, disability, accidental death and dismemberment and travel accident insurance plans and programs. In addition, during the Employment Period, Executive shall be eligible to participate in all pension, retirement, savings and similar employee
benefit plans and programs maintained from time-to-time by the Company for the benefit of its senior executives generally (for the avoidance of doubt, other than any equity or cash incentive plans). All participation in any such plans or programs is
governed by the terms of the applicable plan or program. Nothing in this Agreement is intended to alter the provisions of any Company benefit plan or program. 

2.7 Dues. During the Employment Period, the Company shall pay or promptly reimburse Executive for annual dues for membership in
professional organizations, to the extent that such dues are for the purpose of Executive maintaining continuing educational requirements and/or professional licenses directly related to the position in which Executive is employed. 

2.8 Initial Equity Award. As soon as reasonably practicable following the Effective Date, Executive shall be recommended to the
Board to receive time-based and performance-based restricted stock unit awards pursuant to award agreements substantially in the form attached hereto as Exhibits A and B, respectively. 

  
 3 

 2.9 Proration. Any payments or benefits payable to Executive hereunder in respect
of any calendar year during which Executive is employed by the Company for less than the entire year, unless otherwise provided in the applicable plan or arrangement, shall be prorated in accordance with the number of days in such calendar year
during which he is so employed. 
 2.10 Insurance. The Company may, from time to time, apply for and take out, in its
own name and at its own expense, naming itself or one or more of its affiliates as the designated beneficiary (which it may change from time to time), policies for life, health, accident, disability or other insurance upon Executive in any amount or
amounts that it may deem necessary or appropriate to protect its interest. Executive agrees to aid the Company in procuring such insurance by submitting to medical examinations and by completing, executing and delivering such applications and other
instruments in writing as may reasonably be required by an insurance company or companies to which any application or applications for insurance may be made by or for the Company. 

 

	3.	TERMINATION 

 3.1 Definitions. For purposes of this Agreement, the
following terms shall have the indicated meanings: 
 A. “Anticipatory Termination” shall mean the termination of
Executive’s employment by the Company without Cause (but not because of Executive’s Disability or death) or by Executive for Good Reason, in either case within the six-month period immediately prior to the date on which a Change of Control
occurred, which Change of Control is a “change in the ownership or effective control of the corporation or in the ownership of a substantial portion of the assets of the corporation” under Treasury Regulation Section 1.409A-3(i)(5),
provided that it is reasonably demonstrated by Executive that such termination of employment was either (i) at the request of a third party who has taken steps reasonably calculated to effect such Change of Control or (ii) otherwise arose
in connection with or anticipation of such Change of Control. 
 B. “Cause” shall mean: 

(i) Material dishonesty with respect to the Company or any of its subsidiaries, which is not the result of an inadvertent or
innocent mistake of Executive; 
 (ii) Willful misfeasance or nonfeasance of duty by Executive intended to injure or having
the effect of injuring in some material fashion the reputation, business, or business relationships of the Company or any of its subsidiaries or any of their respective officers, directors, or employees; 

(iii) Material violation by Executive of this Agreement or any other agreement with the Company or any of its subsidiaries;

 (iv) Commission by Executive of (A) any felony, (B) any crime involving moral turpitude or (C) any crime
which could reflect in some material fashion unfavorably upon the Company or any of its subsidiaries, in each case other than a minor vehicular offense; or 

(v) Violation of Sections 1.3 or 1.4 above. 

  
 4 

 C. “Change of Control” shall mean a change in control of
the Company which results from the occurrence of any one or more of the following events: 
 (i) The acquisition by any
individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (a “Person”)) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent
(50%) or more of either (A) the then outstanding shares of common stock of the Company (the “Outstanding Company Stock”) or (B) the combined voting power of the then outstanding voting securities of the Company entitled to
vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that the following acquisitions shall not constitute a Change of Control: (A) any acquisition directly from the Company or
any subsidiary, (B) any acquisition by the Company or any subsidiary or by any employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary, or (C) any acquisition by any corporation pursuant to a
reorganization, merger, consolidation or similar business combination involving the Company (a “Merger”), if, following such Merger, the conditions described in subsection (iv) (below) are satisfied; or 

(ii) A reverse merger involving the Company or the parent of the Company (as defined in Section 424(e) of the Internal
Revenue Code of 1986, as amended (the “Code”) or an equivalent non-corporate entity, the “Parent”), in which the Company or the Parent, as the case may be, is the surviving corporation but the shares of common stock of the
Company or the Parent outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, and the shareholders of the Parent immediately prior to the
completion of such transaction hold, directly or indirectly, less than fifty percent (50%) of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of the surviving entity or, if more than one entity
survives the transaction, the controlling entity; or 
 (iii) Individuals who, as of the Effective Date, constitute the Board
(the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a member of the Board subsequent to the Effective Date whose election, or nomination for election
by the Company’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered a member of the Incumbent Board, but excluding, for this purpose, any such individual whose
initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or
consents by or on behalf of a Person other than the Board; or 

  
 5 

 (iv) The effective date of a Merger, unless immediately following such Merger,
(A) substantially all of the holders of the Outstanding Company Voting Securities immediately prior to Merger beneficially own, directly or indirectly, more than fifty percent (50%) of the common stock of the corporation resulting from
such Merger (or its parent corporation) in substantially the same proportions as their ownership of Outstanding Company Voting Securities immediately prior to such Merger, and (B) at least a majority of the members of the board of directors of
the corporation resulting from such Merger (or its parent corporation) were members of the Incumbent Board at the time of the execution of the initial agreement providing for such Merger; or 

(v) The sale or other disposition of all or substantially all of the assets of the Company, unless immediately following such
sale or other disposition, (A) substantially all of the holders of the Outstanding Company Voting Securities immediately prior to the consummation of such sale or other disposition beneficially own, directly or indirectly, more than fifty
percent (50%) of the common stock of the corporation acquiring such assets in substantially the same proportions as their ownership of Outstanding Company Voting Securities immediately prior to the consummation of such sale or disposition, and
(B) at least a majority of the members of the board of directors of such corporation (or its parent corporation) were members of the Incumbent Board at the time of execution of the initial agreement or action of the Board providing for such
sale or other disposition of assets of the Company. 
 Notwithstanding the foregoing provisions of this definition of Change of Control, for purposes of
this Agreement, a Change of Control shall not be deemed to occur unless such event or events would also be a “change in the ownership or effective control of the corporation or in the ownership of a substantial portion of the assets of the
corporation” under Treasury Regulation Section 1.409A-3(i)(5). 
 D. “Disability” shall mean
a disability suffered by Executive because he (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last
for a continuous period of not less than six (6) months, or (ii) is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not
less than six (6) months, receiving income replacement benefits for a period of not less than three (3) months under an accident and health plan covering employees of the Company. 

E. “Good Reason” shall mean any of the following (without Executive’s prior consent): 

(i) A material reduction in Executive’s Base Salary; 

(ii) Following a Change of Control, (A) a material adverse alteration in the nature or status of Executive’s title,
duties or responsibilities, or (B) the assignment of duties or responsibilities inconsistent with Executive’s status, title, duties and responsibilities; 

  
 6 

 (iii) The non-renewal, or delivery of any notice of non-renewal, of this
Agreement by the Company; 
 (iv) Any material breach by the Company of this Agreement; or 

(v) Any failure by the Company to obtain the assumption and performance of this Agreement by any successor (by merger,
consolidation, or otherwise) or assign of all or substantially all of the Company. 
 Notwithstanding any other provision of this Agreement,
Executive’s employment under this Agreement may be terminated during the Employment Period by Executive for Good Reason, if one of the forgoing events shall occur without the prior consent of Executive. Any such termination by Executive for
Good Reason shall be made by Executive providing written notice to the Company specifying the event relied upon for such termination and given within sixty (60) days after such event. Any termination by Executive for Good Reason shall be
effective thirty (30) days after the date Executive has given the Company such written notice setting forth the grounds for such termination with specificity. However, Good Reason shall exist with respect to an above specified matter only if
such matter is not corrected by the Company within thirty (30) days of its receipt of such written notice of such matter from Executive, and in no event shall a termination by Executive more than ninety (90) days following the date of the
event described above be a termination for Good Reason due to such event. 
 F. “Retirement” shall
mean any separation of employment of Executive from the Company, other than a termination for Cause, so long as Executive has had at least five years of continuous service with the Company and/or any of its subsidiaries or affiliates, including
Vantage Drilling Company, and Executive provides at least six months advance notice to the Board of any such planned Retirement, provided that the Compensation Committee determines that such termination of employment shall be treated as a
“Retirement” for purposes of this Agreement. Notwithstanding any other provision of this Agreement to the contrary, and for the avoidance of doubt, upon Retirement, Executive shall be entitled exclusively to the benefits provided in
Section 3.10 hereof, and under no circumstances shall Retirement constitute a Termination Without Cause, or a Termination by Executive with Good Reason. 

G. “Termination Date” shall mean the date Executive is terminated for any reason pursuant to
Section 3.9.2 of this Agreement. 
 3.2 Notice to Cure. Executive may not be terminated for Cause unless and until there
has been delivered to Executive written notice from the Board supplying the particulars of Executive’s acts or omissions that the Board believes constitute Cause, a reasonable period of time (not less than thirty (30) days) has been given
to Executive after such notice to either cure the same or to meet with the Board (but in any event only to the extent the underlying action is capable of being cured), with his attorney if so desired by Executive, and following which the Board by
action of not less than two-thirds of its members (excluding Executive if Executive is then a member of the Board) furnishes to Executive a written resolution specifying in detail its findings that Executive has been terminated for Cause as of the
date set forth in the notice to Executive. 

  
 7 

 3.3 Good Faith Belief. For purposes of this Agreement, no act or failure to act by
Executive shall be considered “willful” if such act is done by Executive in the good faith belief that such act is or was to be beneficial to the Company or one or more of its businesses or subsidiaries or affiliates, or such failure to
act is due to Executive’s good faith belief that such action would be materially harmful to the Company or one of its businesses. Executive’s actions resulting in a violation of law, including but not limited to laws specified in
Section 1.4, shall not constitute a good faith belief for purposes of this Section 3 or this Agreement. 
 3.4 Termination
Without Cause or Termination For Good Reason: Benefits. If Executive’s employment is terminated either by the Company without Cause, but not because of Executive’s Disability or death, or by Executive for Good Reason, if Executive
executes and delivers to the Company a Release Agreement in accordance with Section 3.9.4, Executive shall receive the payments and benefits described in this Section 3.4 unless Executive is entitled to benefits under Section 3.8
below. 
 3.4.1. Base Salary and Annual Bonus. The Company shall pay Executive an amount equal to two
(2) times the sum of Executive’s annual Base Salary and Target Annual Bonus Opportunity, which shall be paid in substantially equal installments in accordance with the Company’s normal payroll practices commencing on the sixtieth
(60th) day following the Termination Date through the second (2nd) anniversary of the Termination Date, provided that the first such payment shall include any amounts that would have otherwise been paid during the period from the
Termination Date through the sixtieth (60th) day following the Termination Date. 
 3.4.2. Stock Awards.
If there is a Change of Control, termination without Cause or termination for Good Reason, any outstanding equity-based awards under any long-term incentive plans or programs as Company may adopt from time to time (“Stock Awards”) which
Executive has received shall be treated in accordance with the terms of the applicable plan and award agreement. 
 3.4.3.
Expenses. All accrued compensation and unreimbursed expenses through the Termination Date. Such amounts shall be paid to Executive in a lump sum in cash within thirty (30) days after the Termination Date. 

3.4.4. Mitigation. Executive shall be free to accept other employment during such period, and there shall be no
offset of any employment compensation earned by Executive in such other employment during such period against payments due Executive under this Section 3, and there shall be no offset in any compensation received from such other employment
against the Base Salary set forth above. 
 3.5 Termination In Event of Death: Benefits. If Executive’s employment is
terminated by reason of Executive’s death during the Employment Period, this Agreement shall terminate, except as provided herein, without further obligation to Executive’s legal representatives under this Agreement, other than for payment
of all accrued compensation and benefits which shall be paid as otherwise provided in this Agreement, unreimbursed expenses which shall be reimbursed in accordance with the Company’s reimbursement policy, and a pro-rated portion (based on the
number of days Executive was employed by the Company during the 

  
 8 

 
full applicable year) of such annual cash bonus, if any, as Executive would otherwise have earned with respect to the year of Executive’s death. Such cash bonus, if any, shall be paid to
Executive’s estate or beneficiary, as applicable, at such time that such cash bonus would have been paid if Executive had remained employed. Additionally, in the event of Executive’s death during the Employment Period, any outstanding
Stock Awards which Executive has received shall be treated in accordance with the terms of the applicable plan and award agreement. 

3.6 Termination In Event of Disability: Benefits. If Executive’s employment is terminated by reason of Executive’s
Disability during the Employment Period, this Agreement shall terminate, except as provided herein, without further obligation to Executive under this Agreement, other than for payment of all accrued compensation and benefits which shall be paid as
otherwise provided in this Agreement, unreimbursed expenses which shall be reimbursed in accordance with the Company’s reimbursement policy, and a pro-rated portion (based on the number of days Executive was employed by the Company during the
full applicable year) of such annual cash bonus, if any, as Executive would otherwise have earned with respect to the year of Executive’s termination of employment. Such cash bonus, if any, shall be paid to Executive at such time that such cash
bonus would have been paid if Executive had remained employed. In addition, if Executive’s employment is terminated by reason of Executive’s Disability during the Employment Period, any outstanding Stock Awards which Executive has received
shall be treated in accordance with the terms of the applicable plan and award agreement. 
 3.7 Voluntary Termination by Executive
and Termination for Cause: Benefits. Executive may terminate his employment with the Company without Good Reason by giving written notice of his intent and stating an effective Termination Date at least thirty (30) days after the date
of such notice; provided, however, that the Company may accelerate such effective date by paying Executive through the proposed Termination Date and also vesting awards that would have vested but for this acceleration of the proposed Termination
Date. Upon such a termination by Executive, except as provided in Section 5, or upon termination for Cause by the Company, this Agreement shall terminate and the Company shall pay to Executive all accrued compensation and benefits and
unreimbursed expenses through the Termination Date. Such amounts shall be paid to Executive in a lump sum in cash within thirty (30) days after the Termination Date. In addition, any outstanding Stock Awards which Executive has received shall
be treated in accordance with the terms of the applicable plan and award agreement. 
 3.8 Change of Control: Benefits. 

3.8.1. If (a) Executive’s employment is terminated either (i) by the Company without Cause, but not
because of Executive’s Disability or death, or (ii) by Executive for Good Reason, (b) Executive’s Termination Date is during the period beginning six (6) months immediately preceding a Change of Control and ending
twenty-four months after the date of the Change of Control, provided that if Executive’s Termination Date is prior to the date of a Change of Control such termination is an Anticipatory 

  
 9 

 
Termination, and (c) Executive executes and delivers to the Company a Release Agreement in accordance with Section 3.9.4, Executive shall receive the following payments and benefits in
lieu of any payments or benefits under Section 3.4.1 herein: 
 (i) Base Salary and Annual Bonus. The Company
shall pay Executive an amount equal to the sum of Executive’s Base Salary plus Executive’s Average Bonus Amount, multiplied by three (3) (such amount, the “CIC Severance Amount”), which shall be paid in substantially equal
installments in accordance with the Company’s normal payroll practices commencing on the sixtieth (60th) day following the Termination Date through the third (3rd) anniversary of the Termination Date, provided that the first such
payment shall include any amounts that would have otherwise been paid during the period from the Termination Date through the sixtieth (60th) day following the Termination Date. For purposes of this Section 3.8.1.i, “Average Bonus
Amount” means the amount equal to the annual average of the annual bonuses earned in respect of a fiscal year of the Company that was paid or payable to Executive by the Company and any subsidiary for each of the three fiscal years of the
Company that immediately precede the fiscal year in which the Change of Control occurs (or which immediately precede Executive’s Termination Date if a Change of Control has not yet occurred), or in any case such lesser number of full fiscal
years of the Company as Executive was employed by the Company, but not less than the greater of (A) Executive’s highest Target Annual Bonus Opportunity during any of such three preceding fiscal years or (B) Executive’s Target
Annual Bonus Opportunity for the fiscal year in which the Change of Control occurs (or the year in which Executive’s Termination Date occurs if a Change of Control has not yet occurred). Notwithstanding the foregoing, if Executive’s
termination of employment is an Anticipatory Termination, then, in lieu of any payments pursuant to the first sentence of this Section 3.8.1.i, Executive’s payments shall commence or continue in accordance with Section 3.4.1
(including, without limitation, the requirements of Section 3.9.4), except that (x) the payments shall continue through third (3rd) anniversary of the Termination Date and (y) the amount of each payment made following the Change
of Control shall be substantially equally adjusted such that the aggregate amount of payments received by Executive pursuant to Section 3.4.1 and this Section 3.8.1.i through the third (3rd) anniversary of the Termination Date equals
the CIC Severance Amount. 
 (ii) Treatment of Stock Awards. Any outstanding Stock Awards which Executive has received
shall be treated in accordance with the terms of the applicable plan and award agreement. 
 (iii) Outplacement
Assistance. The Company shall provide Executive with outplacement services, for a twelve (12) month period commencing on the Termination Date, or in the event of an Anticipatory Termination the date of the occurrence of the Change of
Control, in an aggregate amount not to exceed $20,000. The Company shall establish reasonable procedures for the designation, review and approval of outplacement services, as well as for the payment or reimbursement of the charges for such services.
All requests for payment or reimbursement of outplacement services must be submitted to the Company within eighteen (18) months following the Termination Date, or in the event of an Anticipatory Termination the date of the occurrence of the
Change of Control, and, upon receipt and approval, will be paid or reimbursed by the Company within thirty (30) days thereafter, subject to Section 9 hereof. 

  
 10 

 3.9 Termination Procedure. 

3.9.1. Notice of Termination. Any termination of Executive’s employment by the Company or by Executive
during the Employment Period (other than pursuant to Section 3.5) shall be communicated by written Notice of Termination to the other party. For purposes of this Agreement, a “Notice of Termination” shall mean a notice indicating the
specific termination provision in this Agreement relied upon and setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive’s employment under that provision. 

3.9.2. Termination Date. “Termination Date” shall mean (i) if Executive’s employment is
terminated by his death, the date of his death, (ii) if Executive’s employment is terminated pursuant to Section 3.6, thirty (30) days after the date of receipt of the Notice of Termination (provided that Executive does not
return to the substantial performance of his duties on a full-time basis during such thirty (30) day period), (iii) if Executive’s employment is terminated voluntarily without Good Reason, the date determined in accordance with
Section 3.7, and (iv) if Executive’s employment is terminated for any other reason, the date on which a Notice of Termination is given or any later date (within thirty (30) days after the giving of such notice) set forth in such
Notice of Termination. 
 3.9.3. Mitigation. Executive shall not be required to mitigate damages with respect
to the termination of his employment under this Agreement by seeking other employment or otherwise, and there shall be no offset against amounts due Executive under this Agreement on account of subsequent employment except as specifically provided
in this Agreement. Additionally, the Company’s obligation to make the payments provided for in this Agreement, and otherwise to perform its obligations hereunder, shall, subject to Section 25 hereof, not be affected by any other
circumstances, including, without limitation, any counterclaim, recoupment, defense or other right which the Company may have against Executive or others. 

3.9.4. Release Agreement. Notwithstanding any provision of this Agreement to the contrary, in order to receive
the benefits upon termination payable under this Section 3 (the “Termination Benefits”), Executive must first execute a release agreement (the “Release Agreement”) on a form provided by the Company, whereby Executive agrees
to release and waive, in return for such benefits, any claims that Executive may have against the Company and its subsidiaries, including, without limitation, for unlawful discrimination (e.g., Title VII of the U.S. Civil Rights Act);
provided, however, the Release Agreement shall not release any claim by or on behalf of Executive for any severance payment or benefit that is provided under this Agreement. Executive must return the executed Release Agreement and any applicable
revocation period must lapse within sixty (60) days of the Termination Date. The Company shall also execute the Release Agreement following the Company’s receipt of Executive’s executed and fully effective Release Agreement; provided,
however, that for the avoidance of doubt the Company shall not be required to release any claims pursuant to the Release Agreement. Notwithstanding any provision herein to the contrary, no Termination Benefits shall be payable or provided by the
Company unless and until the Release Agreement has been 

  
 11 

 
executed by Executive, has not been revoked, and is no longer subject to revocation by Executive. The Termination Benefits shall be paid or provided by the Company at the end of such 60-day
period, but only if the Release Agreement has been properly executed by Executive and is not revocable, and has not been revoked, at that time, regardless of the date on which the Release Agreement was actually executed by Executive. If the
conditions set forth in the preceding sentence are not satisfied by Executive, the Termination Benefits hereunder shall be forfeited. 

3.10 Treatment of Benefits Upon Retirement. Upon the Retirement of Executive, all Stock Awards granted to Executive through the
date of Retirement shall be treated in accordance with Section 3.4.2. 
 3.11 Certain Excise Tax Matters. 

3.11.1. Notwithstanding any other provision of this Agreement to the contrary, if any payment or benefit by or from the
Company or any of its affiliates or successors to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise would be subject to the Excise Tax (as hereinafter
defined in Section 3.11.6) (all such payments and benefits being collectively referred to herein as the “Payments”), then except as otherwise provided in Section 3.11.2, the Payments shall be reduced (but not below zero) or
eliminated (as further provided for in Section 3.11.3) to the extent the Independent Tax Advisor (as hereinafter defined in Section 3.11.5) shall reasonably determine is necessary so that no portion of the Payments shall be subject to the
Excise Tax. 
 3.11.2. Notwithstanding the provisions of Section 3.11.1, if the Independent Tax Advisor
reasonably determines that Executive would receive, in the aggregate, a greater amount of the Payments on an after-tax basis (after including and taking into account all applicable federal, state, and local income, employment and other applicable
taxes and the Excise Tax) if the Payments were not reduced or eliminated pursuant to Section 3.11.1, then no such reduction or elimination shall be made notwithstanding that all or any portion of the Payments may be subject to the Excise Tax.

 3.11.3. For purposes of determining which of Section 3.11.1 and Section 3.11.2 shall be given effect, the
determination of which of the Payments shall be reduced or eliminated to avoid the Excise Tax shall be made by the Independent Tax Advisor, provided that the Independent Tax Advisor shall reduce or eliminate, as the case may be, the Payments in the
following order (and within the category described in each of the following Sections 3.11.3.1 through 3.11.3.5, in reverse order beginning with the Payments which are to be paid farthest in time except as otherwise provided in Section 3.11.3.4)
and in accordance with Section 409A of the Code: 
 3.11.3.1 by first reducing or eliminating the portion of the
Payments otherwise due and which are not payable in cash (other than that portion of the Payments subject to Sections 3.11.3.4 and 3.11.3.5); 

  
 12 

 3.11.3.2 then by reducing or eliminating the portion of the Payments
otherwise due and which are payable in cash (other than that portion of the Payments subject to Sections 3.11.3.3, 3.11.3.4 and 3.11.3.5); 

3.11.3.3 then by reducing or eliminating the portion of the Payments otherwise due to or for the benefit of Executive
pursuant to the terms of this Agreement and which are payable in cash; 
 3.11.3.4 then by reducing or eliminating the
portion of the Payments otherwise due that represent equity-based compensation, such reduction or elimination to be made in reverse chronological order with the most recent equity-based compensation awards reduced first; and 

3.11.3.5 then by reducing or eliminating the portion of the Payments otherwise due to or for the benefit of Executive
pursuant to the terms of this Agreement and which are not payable in cash. 
 3.11.4. The Independent Tax
Advisor shall provide its determinations, together with detailed supporting calculations and documentation, to the Company and Executive for their review no later than ten (10) days after the Termination Date. The determinations of the
Independent Tax Advisor under this Section 3.11 shall, after due consideration of the Company’s and Executive’s comments with respect to such determinations and the interpretation and application of this Section 3.11, be final
and binding on all parties hereto absent manifest error. The Company and Executive shall furnish to the Independent Tax Advisor such information and documents as the Independent Tax Advisor may reasonably request in order to make the determinations
required under this Section 3.11. 
 3.11.5. For purposes of this Section 3.11, “Independent Tax
Advisor” shall mean a lawyer with a nationally recognized law firm, a certified public accountant with a nationally recognized accounting firm, or a compensation consultant with a nationally recognized actuarial and benefits consulting firm, in
each case with expertise in the area of executive compensation tax law, who shall be selected by the Company and shall be acceptable to Executive (Executive’s acceptance not to be unreasonably withheld, conditioned or delayed), and all of whose
fees and disbursements shall be paid by the Company. 
 3.11.6. As used in this Agreement, the term “Excise
Tax” means, collectively, the excise tax imposed by Section 4999 of the Code, together with any interest thereon, any penalties, additions to tax, or additional amounts with respect to such excise tax, and any interest in respect of such
penalties, additions to tax or additional amounts. 
 3.12 Sole Payments. The payments and benefits provided in this Agreement
are the sole payments and benefits to be provided to Executive in the event of Executive’s termination of employment, including, without limitation, under any severance or change of control severance plan or policy sponsored or maintained by
the Company or any affiliate or any predecessor or successor of the Company. 

  
 13 

	4.	DIRECTOR POSITIONS 

 Executive agrees that upon termination of employment, for any
reason, at the request of the Chairman of the Board, he will immediately tender his resignation from any and all Board and other positions held with the Company and/or any of its subsidiaries and affiliates. The Board is hereby empowered to remove
Executive from any such position if Executive fails to resign as required by the immediately preceding sentence. 
  

	5.	NON-COMPETITION, NON-SOLICITATION, AND CONFIDENTIALITY 

 5.1 Company’s Trade
Secrets and Goodwill. The Company shall provide Executive with its trade secrets, goodwill, and confidential information of the Company and contact with the Company’s customers and potential customers. Executive agrees that the business
of the Company is highly competitive and that the trade secrets, goodwill, and confidential information of the Company is of primary importance to the success of the Company. In consideration of all of the foregoing, and in recognition of these
conditions, and specifically for being provided trade secrets, goodwill, and confidential information, Executive agrees as follows: 
 5.2
Non-Competition During Employment. Executive agrees during the Basic Term, and any extension of the Basic Term under this Agreement, he will not compete with the Company by engaging in the conception, design, development, production,
marketing, or servicing of any product or service that is substantially similar to the products or services which the Company or any of its subsidiaries provides, and that he will not work for, in any capacity (including, without limitation, as a
consultant), assist, or become affiliated with as an owner, partner, member, agent, representative or creditor of, either directly or indirectly, any individual or business which offers or performs services, or offers or provides products
substantially similar to the services and products provided by Company or any of its subsidiaries. 
 5.3 Conflicts of
Interest. Executive agrees that during the Basic Term, and any extension of the Basic Term under this Agreement, he will not engage, either directly or indirectly, in any activity which might adversely affect the Company or its affiliates (a
“Conflict of Interest”), including ownership of a material interest in any supplier, contractor, distributor, subcontractor, customer or other entity with which the Company or any of its subsidiaries does business or accepting any material
payment, service, loan, gift, trip, entertainment, or other favor from a supplier, contractor, distributor, subcontractor, customer or other entity with which the Company or any of its subsidiaries does business, and that Executive will promptly
inform the Board as to each offer received by Executive to engage in any such activity. Executive further agrees to disclose to the Board any other facts of which Executive becomes aware which might in Executive’s good faith judgment reasonably
be expected to involve or give rise to a Conflict of Interest or potential Conflict of Interest. 
 5.4 Non-Competition After
Termination. In further consideration of the Company providing Executive with its confidential information, trade secrets, goodwill, and proprietary business information, Executive agrees that he shall not, at any time during the period of
one (1) year after Executive’s Termination Date, for any reason, within any market or country in which the Company or any of its subsidiaries has operated assets or provided services, or formulated a

  
 14 

 
plan to operate its assets or provide services during the last twelve (12) months of Executive’s employ, engage in or contribute Executive’s knowledge to any work which is
competitive with or similar to a product, process, apparatus, services, or development on which Executive worked or with respect to which Executive had access to while employed by the Company or its subsidiaries; provided, however, that the one
(1) year period set forth in this Section 5.4 shall be a two (2) year period in the case of an Executive whose employment is terminated due to Retirement. 

5.4.1. In the event that Executive receives any payment of Base Salary or other severance benefits from the Company subsequent to his
Termination Date, the period of Executive’s non-competition shall continue for the duration of such payments to Executive, but in no event shall the period of non-competition exceed a period of two (2) years after Executive’s
Termination Date, even should Executive continue to receive payments of Base Salary following such two (2) year period. 

5.4.2. It is understood and agreed that the geographical area set forth in this covenant is divisible so that if this clause is invalid
or unenforceable in an included geographic area, that area is severable and the clause remains in effect for the remaining included geographic areas in which the clause is valid. 

5.5 Non-Solicitation of Customers. In further consideration of the Company providing Executive with its confidential
information, trade secrets, and proprietary business information, Executive further agrees that for a period of one (1) year after Executive’s Termination Date (or for a period of two (2) years after termination due to Retirement), he
will not solicit or accept any business similar in nature to the services provided by the Company or any of its subsidiaries from any customer or client or prospective customer or client with whom Executive dealt or solicited while employed by
Company or any of its subsidiaries during the last twelve (12) months of his employment. 
 5.6 Non-Solicitation of
Employees. Executive agrees that for the duration of the Employment Period, and for a period of one (1) year after Executive’s Termination Date (or for a period of two (2) years after termination due to Retirement), he will
not either directly or indirectly, on his own behalf or on behalf of others, solicit, attempt to hire, or hire any person employed by Company or any of its subsidiaries, or otherwise providing services to any of them, to work or otherwise provide
services for Executive or for another entity, firm, corporation, or individual. 
 5.7 Confidential Information. Executive
further agrees that he will not, except as the Company may otherwise consent or direct in writing, reveal or disclose, sell, use, lecture upon, publish or otherwise disclose to any third party any Confidential Information or proprietary information
of the Company or any of its subsidiaries, or authorize anyone else to do these things at any time either during or subsequent to his employment with the Company. This Section 5.7 shall continue in full force and effect after termination of
Executive’s employment and after the termination of this Agreement. Executive shall continue to be obligated under the Confidential Information Section of this Agreement not to use or to disclose Confidential Information of the Company so long
as it shall not be widely publicly available. Executive’s obligations under this Section 5.7 with respect to any specific Confidential Information and 

  
 15 

 
proprietary information shall cease when that specific portion of the Confidential Information and proprietary information becomes widely publicly known, in its entirety and without combining
portions of such information obtained separately. It is understood that such Confidential Information and proprietary information of the Company includes, without limitation, matters that Executive conceives or develops, as well as matters Executive
learns from other employees of Company or any of its subsidiaries. Confidential Information is defined to include, without limitation, information: (1) disclosed to or known by Executive as a consequence of or through his employment with the
Company or any of its subsidiaries; (2) not widely and generally known outside the Company and its subsidiaries; and (3) which relates to any aspect of the Company, any of its subsidiaries or any of their respective businesses, finances,
operation plans, budgets, research, or strategic development. “Confidential Information” includes, but is not limited to the Company’s or any of its subsidiaries’ trade secrets, proprietary information, financial documents, long
range plans, customer lists, employer compensation, marketing strategy, data bases, costing data, computer software developed by the Company or any of its subsidiaries, investments made by the Company or any of its subsidiaries, and any information
provided to the Company or any of its subsidiaries by a third party under restrictions against disclosure or use by the Company or others. 

5.8 Original Material. Executive agrees that any inventions, discoveries, improvements, ideas, concepts or original works of
authorship relating directly to the Company’s business, including without limitation information of a technical or business nature such as ideas, discoveries, designs, inventions, improvements, trade secrets, know-how, manufacturing processes,
product formulae, design specifications, writings and other works of authorship, computer programs, financial figures, marketing plans, customer lists and data, business plans or methods and the like, which relate in any manner to the actual or
anticipated business or the actual or anticipated areas of research and development of the Company and its divisions and affiliates, whether or not protectable by patent or copyright, that have been originated, developed or reduced to practice by
Executive alone or jointly with others during Executive’s employment with the Company or any of its subsidiaries shall be the property of and belong exclusively to the Company. Executive shall promptly and fully disclose to the Company the
origination or development by Executive of any such material and shall provide the Company with any information that it may reasonably request about such material. Either during the subsequent to Executive’s employment, upon the request and at
the expense of the Company or its nominee, and for no remuneration in addition to that due Executive pursuant to Executive’s employment by the Company, but at no expense to Executive, Executive agrees to execute, acknowledge, and deliver to the
Company or its attorneys any and all instruments which, in the judgment of the Company or its attorneys, may be necessary or desirable to secure or maintain for the benefit of the Company or any of its subsidiaries adequate patent, copyright, and
other property rights in the United States and foreign countries with respect to any such inventions, improvements, ideas, concepts, or original works of authorship embraced within this Agreement. 

5.9 Return of Documents, Equipment & Materials. All writings, records, and other documents and things comprising,
containing, describing, discussing, explaining, or evidencing any Confidential Information, and all equipment, components, parts, tools, and the like in Executive’s custody or possession that have been obtained or prepared in the course of
Executive’s employment with the Company or any of its subsidiaries shall be the exclusive property of the Company, shall not be copied and/or removed from the premises of the 

  
 16 

 
Company, except in pursuit of the business of the Company, and shall be delivered to the Company, without Executive retaining any copies, upon notification of the termination of Executive’s
employment or at any other time requested by the Company. The Company shall have the right to retain, access, and inspect all property of Executive of any kind in the office, work area, and on the premises of the Company, as well as any property of
the Company or any of its subsidiaries maintained off the Company’s premises by Executive, upon termination of Executive’s employment and at any time during employment by the Company upon termination of Executive’s employment and at
any time during employment by the Company to ensure compliance with the terms of this Agreement. 
 5.10 Reaffirm Obligations.
Upon termination of his employment with the Company, Executive, if requested by Company, shall reaffirm in writing Executive’s recognition of the importance of maintaining the confidentiality of the Company’s Confidential Information and
proprietary information, and reaffirm any other obligations set forth in this Agreement. 
 5.11 Prior Disclosure. Executive
represents and warrants that he has not used or disclosed any Confidential Information he may have obtained from Company prior to signing this Agreement, in any way inconsistent with the provisions of this Agreement. 

5.12 Confidential Information of Prior Companies. Executive will not disclose or use during the period of his employment with
the Company any proprietary or Confidential Information or copyright works which Executive may have acquired because of employment with an employer other than the Company or acquired from any other third party, whether such information is in
Executive’s memory or embodied in a writing or other physical form. 
 5.13 Non-Disparagement. At no time during or after
Executive’s employment with the Company shall Executive make any false or disparaging statements or remarks about or concerning the Company, its subsidiaries or affiliates, or any of their respective directors, officers, employees, products or
services, in each case except (a) for disparaging statements or remarks to Company personnel in the good faith performance of Executive’s proper duties for the Company while Executive remains employed by the Company or (b) for
truthful statements required to be made by a subpoena, court order or other applicable legal requirement. 
 5.14 Rights Upon
Breach. If Executive breaches, any of the provisions contained in Section 5 of this Agreement (the “Restrictive Covenants”), the Company shall have the following rights and remedies, each of which rights and remedies shall be
independent of the others and severally enforceable, and each of which is in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity: 

(a) Specific Performance. The right and remedy to have the Restrictive Covenants specifically enforced by any court of competent
jurisdiction (without the necessity of the Company to post any bond), it being agreed that any breach of the Restrictive Covenants would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the
Company. 
 (b) Accounting. The right and remedy to require Executive to account for and pay over to the Company all
compensation, profits, monies, accruals, increments or other benefits derived or received by Executive as the result of any action constituting a breach of the Restrictive Covenants. 

  
 17 

 (c) Severance Cessation and Recovery. The right and remedy to cease the further
payment or provision of severance compensation and/or benefits to Executive, and to require Executive to repay to the Company all severance compensation and/or benefits previously paid or provided to Executive. 

5.15 Remedies For Violation of Non-Competition or Confidentiality Provisions. Without limiting the right of the Company to
pursue all other legal and equitable rights available to it for violation of any of the obligations and covenants made by Executive herein, it is agreed that: 

(a) the skills, experience and contacts of Executive are of a special, unique, unusual and extraordinary character which give them a
peculiar value; 
 (b) because of the business of the Company, the restrictions agreed to by Executive as to time and area contained
in this Agreement are reasonable; and 
 (c) the injury suffered by the Company by a violation of any obligation or covenant in this
Agreement resulting from loss of profits created by (i) the competitive use of such skills, experience contacts and otherwise and/or (ii) the use or communication of any information deemed confidential herein will be difficult to calculate
in damages in an action at law and cannot fully compensate the Company for any violation of any obligation or covenant in this Agreement, accordingly: 

(d) 
 (i)
the Company shall be entitled to injunctive relief to prevent violations thereof and prevent Executive from rendering any services to any person, firm or entity in breach of such obligation or covenant and to prevent Executive from divulging any
confidential information (without the necessity of the Company to post any bond); and 
 (ii) compliance with the Agreement
is a condition precedent to the Company’s obligation to make payments of any nature to Executive, subject to the other provisions hereof. 

(e) Executive waives any objection to the enforceability of the Restrictive Covenants and agrees to be estopped from denying the
legality and enforceability of these provisions. 
 5.16 Severability of Covenants. Executive acknowledges and agrees that the
Restrictive Covenants are reasonable and valid in duration and geographical scope and in all other respects. If any court determines that any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the
Restrictive Covenants shall not thereby be affected and shall be given full effect without regard to the invalid portions. 

  
 18 

 5.17 Court Review. If any court determines that any of the Restrictive Covenants,
or any part thereof, is unenforceable because of the duration or geographical scope of, or scope of activities restrained by, such provision, such court shall have the power to reduce the duration or scope of such provision, as the case may be, and,
in its reduced form, such provision shall then be enforceable. 
 5.18 Enforceability in Jurisdictions. The Company and
Executive intend to and hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such Restrictive Covenants. If the courts of any one or more of such jurisdictions hold the
Restrictive Covenants unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the Company that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of
any other jurisdiction within the geographical scope of such Restrictive Covenants, as to breaches of such Restrictive Covenants in such other respective jurisdictions, such Restrictive Covenants as they relate to each jurisdiction being, for this
purpose, severable into diverse and independent covenants. 
 5.19 Extension of Post-Employment Restrictions. In the event
Executive breaches Section 5 of this Agreement, the restrictive time periods contained in those provisions will be extended by the period of time Executive was in violation of such provisions. 

 

	6.	INDEMNIFICATION 

 6.1 General. The Company agrees that if Executive is made
a party or is threatened to be made a party to any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that Executive is or was a trustee, director or officer of the
Company or any predecessor to the Company or any of their affiliates or is or was serving at the request of the Company, any predecessor to the Company, or any of their affiliates as a trustee, director, officer, member, employee or agent of another
corporation or a partnership, joint venture, limited liability company, trust or other enterprise, including, without limitation, service with respect to employee benefit plans, whether or not the basis of such Proceeding is alleged action in an
official capacity as a trustee, director, officer, member, employee or agent while serving as a trustee, director, officer, member, employee or agent, Executive shall be indemnified and held harmless by the Company to the fullest extent authorized
by applicable law, as the same exists or may hereafter be amended, against all Expenses incurred or suffered by Executive in connection therewith, and such indemnification shall continue as to Executive even if Executive has ceased to be an officer,
director, trustee or agent, or is no longer employed by the Company and shall inure to the benefit of his heirs, executors and administrators. All obligations for indemnification hereunder shall be subject to, and paid in accordance with, applicable
Texas or Delaware law. 
 6.2 Expenses. As used in this Section 6, the term “Expenses” shall include, without
limitation, damages, losses, judgments, liabilities, fines, penalties, excise taxes, settlements, and reasonable costs, attorneys’ fees, accountants’ fees, and disbursements and costs of attachment or similar bonds, investigations, and any
expenses of establishing a right to indemnification under this Agreement. 

  
 19 

 6.3 Partial Indemnification. If Executive is entitled under any provision of this
Agreement to indemnification by the Company for some or a portion of any Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Executive for the portion of such Expenses to which Executive is entitled.

 6.4 Notice of Claim. Executive shall give to the Company prompt notice of any claim made against him for which
indemnification will or could be sought under this Agreement. In addition, Executive shall give the Company such information and cooperation as it may reasonably require and as shall be within Executive’s power. 

6.5 Defense of Claim. With respect to any Proceeding as to which Executive notifies the Company of the commencement thereof:

 (a) The Company will be entitled to participate therein at its own expense; 

(b) Except as otherwise provided below, to the extent that it may wish, the Company will be entitled to assume the defense thereof,
with counsel reasonably satisfactory to Executive (such consent not to be unreasonably withheld, conditioned or delayed), which in the Company’s sole discretion may be regular counsel to the Company and may be counsel to other officers and
directors of the Company or any subsidiary. Executive also shall have the right to employ his own counsel in such action, suit or proceeding if he reasonably concludes that failure to do so would involve a conflict of interest between the Company
and Executive, and under such circumstances the reasonable fees and expenses of such counsel shall be at the expense of the Company. 

(c) The Company shall not be liable to indemnify Executive under this Agreement for any amounts paid in settlement of any action or
claim effected without its written consent. The Company shall not settle any action or claim in any manner which would impose any penalty that would not be paid directly or indirectly by the Company or limitation on Executive without
Executive’s written consent. Neither the Company nor Executive will unreasonably withhold or delay their consent to any proposed settlement. 

6.6 Non-exclusivity. The right to indemnification and the payment of expenses incurred in defending a Proceeding in advance of
its final disposition conferred in this Section 6 shall not be exclusive of any other right which Executive may have or hereafter may acquire under any statute or certificate of incorporation or by-laws of the Company or any subsidiary,
agreement, vote of shareholders or disinterested directors or trustees or otherwise. 
  

	7.	BREACH 

 Executive agrees that any breach of restrictive covenants above cannot be
remedied solely by money damages, and that in addition to any other remedies the Company may have, the Company is entitled to obtain injunctive relief against Executive. Nothing herein, however, shall be construed as limiting the Company’s
right to pursue any other available remedy at law or in equity, including recovery of damages and termination of this Agreement and/or any payments that may be due pursuant to this Agreement. 

  
 20 

	8.	RIGHT TO ENTER AGREEMENT 

 Executive represents and covenants to Company that he has full
power and authority to enter into this Agreement and that the execution of this Agreement will not breach or constitute a default of any other agreement or contract to which he is a party or by which he is bound. 

 

	9.	COMPLIANCE WITH SECTION 409A. 

 9.1 Separation from Service.
Notwithstanding anything to the contrary in this Agreement, with respect to any amounts payable to Executive under this Agreement in connection with a termination of Executive’s employment that would be considered “non-qualified deferred
compensation” under Section 409A of the Code, in no event shall a termination of employment be considered to have occurred under this Agreement unless such termination constitutes Executive’s “separation from service” with
the Company as such term is defined in Treasury Regulation Section 1.409A-1(h), and any successor provision thereto (“Separation from Service”). 

9.2 Section 409A Compliance; Payment Delays. 

A. Notwithstanding anything to the contrary in this Agreement, to the maximum extent permitted by applicable law, the severance
payments payable to Executive pursuant to this Agreement shall be made in reliance upon Treasury Regulation Section 1.409A-1(b)(9)(iii) (relating to separation pay plans) or Treasury Regulation Section 1.409A-1(b)(4) (relating to
short-term deferrals). However, to the extent any such payments are treated as “non-qualified deferred compensation” subject to Section 409A of the Code, and if Executive is deemed at the time of his Separation from Service to be a
“specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, then to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a
prohibited payment under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive’s termination benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the
date of Executive’s Separation from Service or (ii) the date of Executive’s death. Upon the earlier of such dates, all payments deferred pursuant to this Section 9 shall be paid in a lump sum to Executive (or Executive’s
estate), without interest. 
 B. The determination of whether Executive is a “specified employee” for purposes of
Section 409A(a)(2)(B)(i) of the Code as of the time of his Separation from Service shall be made by the Company in accordance with the terms of Section 409A of the Code, and applicable guidance thereunder (including without limitation
Treasury Regulation Section 1.409A-1(i) and any successor provision thereto). 
 9.3 Section 409A; Separate
Payments. This Agreement is intended to be written, administered, interpreted and construed in a manner such that no payment or benefits provided under this Agreement become subject to (a) the gross income inclusion set forth within
Section 409A(a)(1)(A) of the Code or (b) the interest and additional tax set forth within Section 409A(a)(1)(B) of the Code (collectively, “Section 409A Penalties”), including, where appropriate, the construction of defined
terms to have meanings that would not cause the imposition of Section 409A Penalties. Notwithstanding the preceding, in no event shall the  

  
 21 

 
Company or any of its affiliates be required to provide a tax gross up payment to or otherwise reimburse Executive with respect to Section 409A Penalties or otherwise in connection with any
taxes or penalties owed by Executive, and in no event is any particular tax treatment of any income recognized by Executive in connection with this Agreement guaranteed. For purposes of Section 409A of the Code (including, without limitation,
for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), each payment that Executive may be eligible to receive under this Agreement shall be treated as a separate and distinct payment and shall not collectively be treated as a single
payment. 
 9.4 In-kind Benefits and Reimbursements. Notwithstanding anything to the contrary in this Agreement or in any
Company policy with respect to such payments, in-kind benefits and reimbursements provided under this Agreement during any tax year of Executive shall not affect in-kind benefits or reimbursements to be provided in any other tax year of Executive
and are not subject to liquidation or exchange for another benefit. Notwithstanding anything to the contrary in this Agreement, reimbursement requests must be timely submitted by Executive and, if timely submitted, reimbursement payments shall be
made to Executive as soon as administratively practicable following such submission in accordance with the Company’s policies regarding reimbursements, but (except as provided below in Section 9.5) in no event later than the last day of
Executive’s taxable year following the taxable year in which the expense was incurred. 
 9.5 Reformation. If any
provision of this Agreement would cause Executive to occur any additional tax under Section 409A of the Code, the parties will in good faith attempt to reform the provision in a manner that maintains the original intent of the applicable
provision without violating the provision of Section 409A of the Code. 
  

	10.	ENFORCEABILITY 

 The agreements contained in the restrictive covenant provisions of this
Agreement are independent of the other agreements contained herein. Accordingly, failure of the Company to comply with any of its obligations outside of Section 5 does not excuse Executive from complying with the agreements contained herein.

  

	11.	SURVIVABILITY 

 The agreements contained in Section 5, and any other obligations of
Executive which by their nature require performance or satisfaction following termination of Executive’s employment, shall survive the termination of this Agreement for any reason. 

 

	12.	ASSIGNMENT 

 This Agreement cannot be assigned by Executive. The Company may assign this
Agreement only to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and assets of the Company, provided such successor expressly agrees in writing to assume and
perform this Agreement in the same manner and to the same extent that the Company would have been required to perform it if no such succession and assignment had taken place. Except in instances of assignment by operation of law, failure of the
Company to obtain such written agreement prior to the effectiveness of any such succession shall be a material breach of this Agreement. 

  
 22 

	13.	BINDING AGREEMENT 

 Executive understands that his obligations under this Agreement are
binding upon Executive’s heirs, successors, personal representatives, and legal representatives. 
  

	14.	NOTICES 

 All notices pursuant to this Agreement shall be in writing and sent certified
mail, return receipt requested, addressed as set forth below, or by delivering the same in person to such party, or by transmission by facsimile to the number set forth below. Notice deposited in the United States Mail, mailed in the manner
described hereinabove, shall be effective upon deposit. Notice given in any other manner shall be effective only if and when received: 
 If to Executive:

 At Executive’s most recent home address as set forth in the employment records of the Company 

If to the Company: 
 Vantage Drilling International 

Attn: General Counsel 
 777 Post Oak Blvd., Suite 800 

Houston, TX 77056 
  

	15.	WAIVER 

 No waiver by either party to this Agreement of any right to enforce any term or
condition of this Agreement, or of any breach hereof, shall be deemed a waiver of such right in the future or of any other right or remedy available under this Agreement. Except as otherwise provided herein, Executive’s or the Company’s
failure to insist upon strict compliance with any provision hereof or any other provision of this Agreement or the failure to assert any right Executive or the Company may have hereunder, shall not be deemed to be a waiver of such provision or right
or any other provision or right of this Agreement. 
  

	16.	SEVERABILITY 

 If any provision of this Agreement is determined to be void invalid,
unenforceable, or against public policy, such provisions shall be deemed severable from the Agreement, and the remaining provisions of the Agreement will remain unaffected and in full force and effect. The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. 

  
 23 

	17.	ENTIRE AGREEMENT 

 The terms and provisions contained herein shall constitute the entire
agreement between the parties with respect to Executive’s employment with the Company during the Employment Period. This Agreement replaces and supersedes any and all existing agreements entered into between Executive and the Company relating
generally to the same subject matter, if any, and shall be binding upon Executive’s heirs, executors, administrators, or other legal representatives or assigns. 
  

	18.	SECTION HEADINGS 

 The section headings in this Agreement are for convenience of
reference only, and they form no part of this Agreement and shall not affect its interpretation. 
  

	19.	MODIFICATION OF AGREEMENT 

 This Agreement may not be changed or modified or released or
discharged or abandoned or otherwise terminated, in whole or in part, except by an instrument in writing signed by Executive and an officer or other authorized executive of the Company. 

 

	20.	UNDERSTANDING OF AGREEMENT 

 Executive represents and warrants that he has read and
understood each and every provision of this Agreement, and Executive understands that he has the right (and has been afforded the opportunity) to obtain advice from legal counsel of choice, and that Executive has freely and voluntarily entered into
this Agreement. 
  

	21.	GOVERNING LAW 

 This Agreement shall be governed by and construed in accordance with the
laws of the State of Texas, other than the conflicts of law provisions thereof. 
  

	22.	WITHHOLDING 

 All payments hereunder shall be subject to any required withholding of
Federal, state and local taxes pursuant to any applicable law or regulation. 
  

	23.	JURISDICTION AND VENUE. 

 The parties hereto consent to the exclusive jurisdiction of all
state and federal courts located in Harris County, Texas, as well as to the jurisdiction of all courts of which an appeal may be taken from such courts, for the purpose of any suit, action or other proceeding arising out of, or in connection with,
this Agreement or that otherwise arise out of the employment relationship. Each party hereto hereby expressly waives (i) any and all rights to bring any suit, action or other proceeding in or before any court or tribunal other than the courts
described above, and covenants that it will not seek in any manner to resolve any dispute other than as set forth in this paragraph, and (ii) any and all objections either may have to venue, including the inconvenience of such forum, in any of
such courts. In addition, each party hereto consents to 

  
 24 

 
the service of process by personal service or any manner in which notices may be delivered hereunder in accordance with this Agreement. This provision shall not, however, preclude the Company
from obtaining injunctive relief in any court of competent jurisdiction to enforce Section 5 of this Agreement. 
  

	24.	NO PRESUMPTION AGAINST INTEREST. 

 This Agreement has been negotiated, drafted, edited
and reviewed by the respective parties, and therefore, no provision arising directly or indirectly herefrom shall be construed against any party as being drafted by said party. 

 

	25.	CLAWBACK. 

 Notwithstanding any other provisions in this Agreement to the contrary, any
compensation paid to Executive pursuant to this Agreement or any other agreement or arrangement with the Company or any of its subsidiaries will be subject to such deductions and clawback as may be required to be made pursuant to such law,
government regulation or stock exchange listing requirement, or pursuant to any clawback or recoupment policy adopted by the Company or any of its subsidiaries. In no event will the application of any such clawback or recoupment requirement or
policy be deemed to constitute or contribute to the existence of Good Reason. 

  
 25 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first
above written. 
 VANTAGE DRILLING INTERNATIONAL 
  

			
	By:	 	/s/ Thomas R. Bates, Jr.
	Title:	 	Chairman

 EXECUTIVE 
  

	
	/s/ Ihab Toma
	Ihab Toma

 EXHIBIT A 

RESTRICTED STOCK UNIT AWARD AGREEMENT 

(TIME-BASED) 

 EXHIBIT B 

RESTRICTED STOCK UNIT AWARD AGREEMENT 

(PERFORMANCE-BASED)SHAREHOLDERS
aGREEMENT

 

by
and between

 

Oncbiomune
México, s.A. de c.v.

 

as
the Company,

 

and

 

Vitel
Laboratorios, S.A. de C.V. and OncBioMune Pharmaceuticals Inc. as Shareholders 

 

Dated
as of August 19th, 2016

 

 

    	 	 	 

    	 	 	 

    

 

TABLE
OF CONTENTS

 

	 	 	Page
	Article
    I DEFINITIONS	4
	 	 	 
	Section
    1.1	Defined
    Terms	4
	Section
    1.2	Construction	9
	 	 	 
	Article
    II BOARD OF DIRECTORS	 
	 	 	 
	Section
    2.1	Board
    Size	9
	Section
    2.2	Shareholder
    Nominees; By-Law Amendment	9
	Section
    2.3	Frequency
    of Board of Directors’ Meetings	10
	Section
    2.4	Quorum
    and Voting Requirements	10
	 	 	 
	Article
    III SHAREHOLDERS’ MEETINGS; CAPITALIATION AND SHARE OWNERSHIP	10
	 	 	 
	Section
    3.1	Frequency
    of Shareholders’ Meetings	10
	Section
    3.2	Quorum
    and Voting Requirements	11
	Section
    3.3	Major
    Decisions	11
	Section
    3.4	Capitalization
    and Share Ownership.	12
	 	 	 
	Article
    IV REPRESENTATIONS AND WARRANTIES	12
	 	 	 
	Section
    4.1	Enforceability,
    Etc	13
	Section
    4.2	Options
    or Warrants..	13
	 	 	 
	Article
    V ADDITIONAL RIGHTS	13
	 	 	 
	Section
    5.1	Preemptive
    Rights	13
	Section
    5.2	Transfer
    of Common Shares	13
	 	 	 
	Article
    VI COMPANy SUBSIDIARIES	16
	 	 	 
	Section
    6.1	Company
    Subsidiaries	16
	 	 	 
	Article
    VII OTHER AGREEMENTS	16
	 	 	 
	Section
    7.1	Company’s
    By-laws and Conflict Of Interest	16
	Section
    7.2	Patents,
    Sanitary Registrations and Licenses	18
	Section
    7.3	Board
    of Directors and Officers of the Company on the Closing Date.	20
	Section
    7.4	Dividends	21
	Section
    7.5	Funding..	21

 

    	 	 	 

    	 	 	 

    

 

	Article
    VIII FINANCIAL INFORMATION AND AUDITS	21
	 	 	 
	Section
    8.1	Periodic
    Information	21
	Section
    8.2	Visits
    and Inspection	21
	Section
    8.3	Audits	21
	Section
    8.4	Bank
    Accounts	21
	 	 	 
	Article
    IX MISCELLANEOUS	22
	 	 	 
	Section
    9.1	Headings	22
	Section
    9.2	Entire
    Agreement	22
	Section
    9.3	Confidentiality	22
	Section
    9.4	Further
    Actions; Cooperation	22
	Section
    9.5	Notices	22
	Section
    9.6	Applicable
    Law	23
	Section
    9.7	Severability	24
	Section
    9.8	Successors
    and Assigns	24
	Section
    9.9	Amendments	24
	Section
    9.10	Waiver	24
	Section
    9.11	Counterparts	24
	Section
    9.12	Injunctive
    Relief	24
	Section
    9.13	SUBMISSION
    TO JURISDICTION	24
	Section
    9.14	Recapitalizations,
    Exchanges, Etc. Affecting the Common Shares; New Issuances	25
	Section
    9.15	Term	25
	Section
    9.16	By-laws	25
	Section
    9.17	Preferential
    Rights for New Projects	25

 

    	 	 -3-	 

    	 	 	 

    

 

SHAREHOLDERS
AGREEMENT (this “Agreement”), dated as of August 19th, 2016, is entered into by and among:

 

	 	(a)	Vitel
    Laboratorios, S.A. de C.V., a sociedad anónima de capital variable, duly formed under the laws of Mexico (“Vitel”)
    herein represented by Mr. Manuel Cosme Odabachian;
	 	 	 
	 	(b)	OncBioMune
    Pharmaceuticals Inc., a corporation duly formed under the laws of Nevada (“OBMP” and collectively
    with Vitel hereinafter as the “Shareholders” and individually, each a “Shareholder”),
    represented herein by Dr. Jonathan Frederic Head;
	 	 	 
	 	(c)	Oncbiomune
    México, a sociedad anónima de capital variable, duly formed under the laws of Mexico (the “Company”
    and collectively with the Shareholders hereinafter as the “Parties” and individually each a “Party”)
    represented herein by Mr. Manuel Cosme Odabachian;

 

WHEREAS,
on March 17, 2016, the Shareholder executed and delivered a Memorandum of Understanding (the “MOU”),
whereby, the Shareholders defined the broad parameters of a Joint Venture between them for the purposes of developing and commercializing
OBMP Vaccine Technology and other OBMP cancer technologies in México, Central and Latin America for the treatment of prostate,
ovarian and various other types of cancer. A complete copy of the MOU is attached hereto as Exhibit A.

 

WHEREAS,
on May 26 2016, the Shareholders incorporated the Company in order to combine their respective assets, resources and areas of
expertise for the purpose of expediting clinical development and marketing of OBMP therapeutic candidates in MALA (as such term
is defined hereinbelow). A complete copy of the incorporation deed of the Company is attached hereto as Exhibit B.

 

WHEREAS,
the Shareholders agreed to enter into this Agreement in order to govern their relationship with respect to the ownership, management
and operation of the Company.

 

NOW,
THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein and for good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto hereby agree as follows:

 

Article
I

DEFINITIONS

 

Section
1.1 Defined Terms. For the purposes of this Agreement, the following terms shall have the following meanings:

 

(a)
“Affiliate” shall mean, in respect of Persons that are legal Persons, all present and future Subsidiaries,
controlling partners and controlling shareholders of such Persons or other entities that are under common control with such Person;
and in the case of natural Persons, the term “Affiliate” shall mean such individuals’ spouse,
and any direct or indirect ascendants or descendants, including parents, grandparents, children and grandchildren.

 

(b)
A Person shall be deemed to “Beneficially Own” securities:

 

(i)
which such Person or any of such Person’s Affiliates, directly or indirectly, owns or has the right to acquire (whether
such right is exercisable immediately or only after the passage of time or upon the satisfaction of one or more conditions (whether
or not within the control of such Person), including compliance with regulatory requirements or otherwise) pursuant to any agreement,
arrangement or understanding in writing, or upon the exercise of conversion rights, exchange rights, other rights, warrants or
options, or otherwise; or

 

    	 	 -4-	 

    	 	 	 

    

 

(ii)
which such Person or any of such Person’s Affiliates, directly or indirectly, has the right to vote or dispose of or has
“Beneficial Ownership” of (as determined pursuant to Rule 13d-3 of the General Rules and Regulations under
the Exchange Act), including pursuant to any agreement, arrangement or understanding, in writing; or

 

(iii)
which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate thereof) with whom such Person (or
any of such Person’s Affiliates) has any agreement, arrangement or understanding, in writing, for the purpose of acquiring,
holding, voting or disposing of any Company Securities.

 

(c)
A Person shall be deemed to “Own” securities which such Person or any of such Person’s Affiliates
directly or indirectly owns or has the immediate right to acquire from a Person (other than from the Company pursuant to this
Agreement) pursuant to any agreement, arrangement or understanding (whether or not in writing) or upon the exercise of conversion
rights, exchange rights, other rights, warrants or options, or otherwise.

 

(d)
“Applicable Law” shall mean, with respect to any Person, all present and future statutes, laws, ordinances,
rules, orders and regulations of any Governmental Authority applicable to such Person or any of its Affiliates, or any of their
respective properties or assets.

 

(e)
“Board” shall mean the board of directors of the Company.

 

(f)
“Business” shall mean the business and activities conducted by the Company from time to time, including
the development and operation of Products in MALA.

 

(g)
“Business Day” shall mean any day other than (i) a Saturday or a Sunday or (ii) a day on which banking
and savings and loan institutions are authorized or required by law to be closed in the United States of America and in Mexico.

 

    	 	 -5-	 

    	 	 	 

    

 

(h)
“By-laws” shall mean the amended by-laws of the Company discussed in Section 7.1(a) herein, and attached
hereto as Exhibit E.

 

(i)
“Common Shares” shall mean the Company’s common stock, par value MXN$1.00 (one Peso 00/100 cents,
legal tender of the Mexican United States) per share, and any and all securities of any kind whatsoever of the Company that may
be issued and outstanding on or after the date hereof in respect of, in exchange for, or upon conversion of common shares pursuant
to a merger, amalgamation, consolidation, share split, share dividend or recapitalization of the Company or otherwise.

 

(j)
“Company Securities” shall mean (i) any Common Shares and (ii) any other securities of the Company entitled
to vote generally including without limitation, in the election of directors of the Company.

 

(k)
“Company” shall have the meaning set forth in the Preamble of this Agreement.

 

(l)
“Dividends” shall mean any dividends (whether paid in cash, Common Shares or otherwise) or other distribution
(in cash or otherwise) paid to the holders of Common Shares of the Company.

 

(m)
“Dollars or US” shall mean the legal tender of the United States of America.

 

(n)
“Exchange Act” shall mean the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder.

 

(o)
“Governmental Authority” shall mean any sovereign government or any political subdivision thereof, whether
federal, state or local, any legislative or judicial body, and any agency, authority, instrumentality, regulatory body, court,
central bank or other entity exercising executive, legislative, judicial, taxing, regulatory, sanitary or administrative powers
or functions of or pertaining to government.

 

(p)
“Major Decision(s)” shall have the meaning set forth in Section 3.3 hereto.

 

(q)
“MALA” shall mean all Mexico and the other the countries and territories defined in Appendix A
hereof.

 

(r)
“Minimum Price” shall have the meaning set forth in Section 5.2(b)(i) hereto.

 

(s)
“New Securities” means any Common Shares of the Company issued after the date hereof as a result of
an increase in the capital stock of the Company.

 

(t)
“Notice of Exercise” shall have the meaning set forth in Section 5.2(b)(ii) hereto.

 

    	 	 -6-	 

    	 	 	 

    

 

(u)
“OBMP” shall have the meaning set forth in the Preamble of this Agreement.

 

(v)
“Offered Shares” shall have the meaning set forth in Section 5.2(b)(i) hereto.

 

(w)
“Party” shall have the meaning set forth in the Preamble of this Agreement.

 

(x)
“Patents” For purposes of this Agreement, the term patents and patent applications obtained by OBMP in the
U.S. and other countries shall mean:

 

-
the patents and patent applications set forth in Exhibit F and such patents and patent applications along with any supplemental
or additional patent applications or registrations or divisionals, reissues, re-examination certificates, continuations, or provisional
applications filed in the future by OBMP that include the Protein Therapeutic Cancer Vaccine identified in such patents for any
or all cancer treatment uses shall be collectively referred to as, the “Base Patents”;

 

-
all future improvements of the technology disclosed in the Base Patents, including, but not limited to, any additional patent
applications that include the Protein Therapeutic Cancer Vaccine for all cancer treatment uses and supplemental or additional
patent registrations or divisionals, reissues, re-examination certificates, continuations, or provisional applications filed in
the future with respect to the Base Patents shall be collectively referred to as, the “Derivative Patents”; and

 

-
all future technology, patents and/or patent applications which include subject matter related to any and all Cancer therapeutic
treatments, medicine, drugs, vaccines, cures, alternative medicine, arboreal therapy, and/or surgical instruments, apparatus and/or
technics, as same may be subject to be protected by a patent in any country and shall be collectively referred to as, the “Other
Patents”.

 

(y)
“Permitted Transferee” shall have the meaning set forth in Section 5.2(a) hereto.

 

(z)
“Permitted Transfer” means any Transfer carried out by a Shareholder to a Permitted Transferee pursuant
to the terms of this Agreement.

 

(aa)
“Person” shall mean any individual, firm, corporation, partnership, limited liability company, business
organization (under any form), trust or other entity, and shall include any successor (by merger, amalgamation or otherwise) of
such entity.

 

(bb)
“Pipeline Products” shall mean the products set forth in Exhibit C and/or that use or
are based on the technology included in the Patents, Base Patents, the Derivative Patents, the Other Patents or use the Trademarks.

 

    	 	 -7-	 

    	 	 	 

    

 

(cc)
“Products” shall mean, the products set forth in Exhibit D hereto, the Pipeline Products,
OBMP Vaccine Technology, OBMP cancer technologies for the treatment of prostate, ovarian and various other types of cancer and
any other technology for medical treatment, drug or medical treatment that use or are based on the technology included in the
Patents, Base Patents, the Other Patents or the Derivative Patents or use the Trademarks.

 

(dd)
“Project” shall mean the development and commercialization the Products.

 

(ee)
“Right of First Refusal” shall have the meaning set forth in Section 5.2(b) hereto.

 

(ff)
“ROFR Deposit” shall have the meaning set forth in Section 5.2(b)(iii) hereto.

 

(gg)
“ROFR Exercise Period” shall have the meaning set forth in Section 5.2(b)(ii) hereto.

 

(hh)
“ROW” shall mean all the countries and territories in the world with exception of the United States
of America and MALA.

 

(ii)
“ROW Opportunity” shall have the meaning set forth in Section 9.17 hereto.

 

(jj)
“Shareholder Director” shall mean the Shareholder Nominee, if any, who are elected or appointed to serve
as members of the Board in accordance with this Agreement.

 

(kk)
“Shareholders’ Meeting” shall have the meaning set forth in Section 3.1.

 

(ll)
“Shareholder Nominee” shall mean such Persons as are so designated by the Shareholders, as such designations
may change from time to time in accordance with this Agreement, to serve as members of the Board pursuant to Section 3.2.

 

(mm)
“Shareholders” shall mean Vitel, OBMP and each Permitted Transferee who becomes a party to or bound
by the provisions of this Agreement in accordance with the terms hereof.

 

(nn)
“Third Party Purchaser” shall have the meaning set forth in Section 5.2(b)(i) hereto.

 

(oo)
“Third Party Sale Agreement” shall have the meaning set forth in Section 5.2(b)(vi) hereto.

 

(pp)
“Trademarks” shall have the meaning set forth in Section 5.2(b)(vi) hereto.

 

    	 	 -8-	 

    	 	 	 

    

 

(qq)
“Transfer” shall mean, with respect to any Company Securities, (i) when used as a verb, to sell, assign,
dispose of, exchange, pledge, charge, encumber, hypothecate or otherwise transfer such Company Securities or any participation
or interest therein, whether directly or indirectly (including by means of any hedging or derivative transactions that may have
a similar effect to the foregoing), or agree or commit to do any of the foregoing; and (ii) when used as a noun, a direct or indirect
sale, assignment, disposition, exchange, pledge, charge, encumbrance, hypothecation, or other transfer of such Company Securities
or any participation or interest therein (or any hedging or derivative transactions that may have a similar effect to the foregoing)
or any agreement or commitment to do any of the foregoing.

 

(rr)
“Vitel” shall have the meaning set forth in the Preamble of this Agreement.

 

(ss)
“Voting Power of the Company” shall mean the total number of votes that may be cast in the election
of directors of the Company if all Company Securities were present and voted at a meeting held for such purpose.

 

Section
1.2 Construction. For the purposes of this Agreement: (i) words (including capitalized terms defined herein) in
the singular shall be held to include the plural and vice versa, and words (including capitalized terms defined herein) of one
gender shall be held to include the other gender as the context requires; (ii) the terms “hereof,” “herein”
and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement
as a whole and not to any particular provision of this Agreement, and Article and Section references are to Articles and Sections
of this Agreement, unless otherwise specified; (iii) the word “including” and words of similar import when used in
this Agreement shall mean “including, without limitation,”; (iv) all references to any period of days shall be deemed
to be to the relevant number of calendar days unless otherwise specified; and (v) all references herein to “$” or
dollars shall refer to United States dollars, unless otherwise specified.

 

Article
II

BOARD OF DIRECTORS

 

Section
2.1 Board Size. The administration and management of the Company will be vested in a Board. The Board of the Company shall
have four (4) principal directors, each of which may have an alternate director. For so long as this Agreement is in effect, the
Board shall not have more than the number of directors aforementioned or, in lieu of any such agreement, as provided in the Company’s
By-laws.

 

Section
2.2 Shareholder Nominees; By-Laws Amendment.

 

(a)
So long as any Shareholder has Ownership of:

 

(i)
Twenty five percent (25%) or more of the Voting Power of the Company, any Shareholder shall be entitled to designate in the Company
two (2) Shareholder Nominees and their respective alternates;

 

(ii)
Twenty five percent (25%) of the Voting Power of the Company, any Shareholder shall not be entitled to designate in the Company
any Shareholder Nominees or their alternates.

 

    	 	 -9-	 

    	 	 	 

    

 

Every
alternate member of the Board will have the right to attend meetings of the Board and to vote at such meetings only in the absence
of its respective principal member. Principal or alternate directors may only be removed and appointed by the Shareholder(s) that
appointed such directors.

 

(b)
So long as OBPM owns at least fifty percent (50%) or more of the Voting Power, it shall have the right to appoint the Chairman
of the Company’s Board of Directors.

 

Section
2.3 Frequency of Board of Directors’ Meetings. The Board shall meet at least four (4) times (quarterly) during each
fiscal year, or whenever a meeting is called in accordance with the Company’s By-laws, at the Company’s corporate
domicile or abroad, as established in the corresponding call.

 

The
Parties hereby agree that meetings of the Board may be carried out by telephone conference or by any other means that allows for
the effective participation of the members of the Board. In such cases, the resolutions adopted thereat will be valid only upon
execution of written resolutions in compliance with the Mexican corporate law (Ley General de Sociedades Mercantiles).

 

Section
2.4 Quorum and Voting Requirements. The Board Meetings of the Company shall be legally convened and held pursuant to the
Company’s By-laws (i) a first call, if at least the majority of its members shall be present; provided that, at least one
member appointed by OBMP and one member appointed by Vitel shall be present, and (ii) to a second or subsequent call, if at least
the majority of its members shall be present, provided that, at least one member appointed by OBMP and one member appointed by
Vitel shall be present.

 

Except
in the case of Major Decisions which will be subject to the attendance and voting requirements set forth in Section 3.3 of this
Agreement, the resolutions adopted by the Board shall be valid if they are adopted by the majority of the members in attendance
at the relevant meeting.

 

Article
III

SHAREHOLDERS’ MEETINGS; CAPITALIZATION AND
SHARE OWNERSHIP

 

Section
3.1 Frequency of Shareholders’ Meetings. The general shareholders’ meeting of the Company (each, a “Shareholders’
Meeting”) shall be convened at least once every fiscal year, or whenever a meeting is called in accordance with
the Company’s By-laws, at the Company’s corporate domicile or abroad, if established in the corresponding call.

 

The
Parties hereby agree that meetings of the Shareholders may be carried out by telephone conference or by any other means that allows
for the effective participation of the Shareholders. In such cases, the resolutions adopted thereat will be valid only upon execution
of written resolutions in compliance with the Mexican corporate law (Ley General de Sociedades Mercantiles).

 

    	 	 -10-	 

    	 	 	 

    

 

Section
3.2 Quorum and Voting Requirements. Shareholders’ Meetings of the Company shall be legally held, pursuant
to (i) a first call, if at least fifty-one percent (51.0%) of the outstanding Common Shares of the Company is represented at the
meeting and (ii) a second or subsequent call, if at least fifty-one percent (51.0%) of the Common Shares of the Company is represented
at the meeting.

 

The
resolutions of the Shareholders’ Meeting shall be valid if they are adopted by the vote of at least fifty-one percent (51.0%)
of the Common Shares of the Company duly represented at the relevant meeting.

 

In
the case of Shareholders’ Meetings of the Company or held to discuss and/or vote Major Decisions, such meetings shall be
legally held, pursuant to (i) a first call, if at least seventy-five percent (75.0%) of the outstanding Common Shares of the Company
are represented at the meeting and (ii) a second or subsequent call, if at least seventy-five percent (75.0%) of the Common Shares
of the Company are represented at the meeting. The resolutions of the Shareholders’ Meeting shall be valid if (i) they are
adopted by the vote of at least seventy-five percent (75.0%) of the Common Shares of the Company duly represented at the relevant
meeting and (ii) both OBMP and Vitel are duly represented at such meeting.

 

Section
3.3 Major Decisions. Notwithstanding anything to the contrary contained herein or in the By-laws of the Company,
and subject to the respective authority of the Shareholders’ Meeting or the Board of Directors under Applicable Law and
the By-laws of the Company, as the case may be, the following matters may only be carried out by the Company (each a “Major
Decision” and collectively, the “Major Decisions”) if previously approved (i) pursuant
to the requirements for Major Decisions set forth in Section 3.2 above or (ii) by a Board of Directors’ Meeting of the Company
with the attendance and affirmative vote of a principal or alternate member of the Board of Directors of the Company appointed
by each of the Parties:

 

(a)
Creating, authorizing a capital increase of or issuing any equity or equity-like security;

 

(b)
Any amalgamation, merger, spin-off, consolidation, sale, reconstitution, reorganization, restructuring or similar transaction;

 

(c)
Any liquidation, winding up, etc., of the Company or any listing or delisting of shares, or any private or public offering of
shares or any de-listing of the shares of the Company;

 

(d)
Any amendment, alteration, change or addition to or repeal of the By-laws of the Company;

 

(e)
Any change to the Business of the Company;

 

(f)
Any incurrence of any indebtedness or guarantees which involve amounts exceeding US$10,000 (ten thousand 00/100 Dollars) per quarter;

 

    	 	 -11-	 

    	 	 	 

    

 

(g)
The exercise of all corporate rights (including but not limited to, voting rights, redemption rights and preferential rights)
attached to or derived from the Company’s interest in any subsidiary of the Company;

 

(h)
The determination, amendment or termination of the Company’s dividend policy;

 

(i)
The determination, amendment or termination of the annual plan, annual budget and business plan of the Company and of any subsidiaries
of the Company;

 

(j)
Approval of the audited financial statements of the Company and of any subsidiary of the Company, where applicable;

 

(k)
The appointment and removal of the Company’s external auditors;

 

(l)
To the extent not specifically approved by the board the disposition (including, without limitation, the sale or the creation
of any lien and encumbrances) of any assets or capital investments by the Company outside of the ordinary course of Business of
the Company;

 

(m)
Except for Permitted Transfers, any transfer of equity interests of the Company in any subsidiary of the Company;

 

(n)
The filing by the Company of any lawsuit or the initiation of any formal alternative dispute resolution procedure;

 

(o)
The creation of any subsidiary, except as contemplated in the Company’s business plan;

 

(p)
Except for Permitted Transfers, the admission of any new shareholder to the Company; and

 

(q)
The granting of powers of attorney for acts of domain in México or its equivalent in any other jurisdiction where the Company
pursues business opportunities.

 

Section
3.4 Capitalization and Share Ownership.

 

(a)
The Company is authorized to issue 10,000 (ten thousand) shares of Common Stock, of which 5,000 (five thousand) shares have been
subscribed for and issued to OBMP and 5,000 (five thousand) shares have been subscribed for and issued to Vitel. The issued and
outstanding shares are validly issued, fully paid, and non-assessable and not issued in violation of the preemptive or other rights
of any person.

 

Article
IV

REPRESENTATIONS AND WARRANTIES

 

(a)
Each Shareholder hereby represents and warrants to the Company and to each other Shareholder as follows:

 

    	 	 -12-	 

    	 	 	 

    

 

Section
4.1 Enforceability, Etc. This Agreement has been duly executed and delivered by such Shareholder. This Agreement constitutes
a legal, valid and binding obligation of such Shareholder, enforceable against such Shareholder in accordance with its terms,
subject to any limitations imposed, if applicable, by bankruptcy, insolvency, or other laws of general application relating to
enforcement of creditors’ rights or general equity principles.

 

(b)
The Company hereby represents and warrants to each of the Shareholders as follows:

 

Section
4.2 Options or Warrants. Except for the Shareholders’ statutory preferential right to subscribe any shares issued
by the Company in connection with capital stock increases, there are no options, warrants, convertible securities, subscriptions,
stock appreciation rights, phantom stock plans or stock equivalents or other rights, agreements, arrangements or commitments (contingent
or otherwise) of any character issued or authorized by the Company relating to the issued or unissued capital stock of the Company
(including, without limitation, rights the value of which is determined with reference to the capital stock or other securities
of the Company) or obligating the Company to issue or sell any shares of capital stock of, or options, warrants, convertible securities,
subscriptions or other equity interests in, the Company. There are no outstanding contractual obligations of the Company to repurchase,
redeem or otherwise acquire any shares of the Company Common Stock of the Company or to pay any dividend or make any other distribution
in respect thereof or to provide funds to, or make any investment (in the form of a loan, capital contribution or otherwise) in,
any person.

 

Article
V

ADDITIONAL RIGHTS

 

Section
5.1 Preemptive Rights. Each of the Shareholders of the Company shall have preemptive rights to subscribe and pay its respective
pro-rata share, based on its respective percentage of ownership interest in the Company, of any New Securities that the
Company may from time to time issue pursuant to the terms and conditions established in the By-laws of the Company, provided that
none of the Shareholders will be entitled to endorse or otherwise transfer their preemptive rights. The Shareholders shall have
the right, for a period of 30 (thirty) Business Days after delivery of notice, to purchase from the Company the New Securities
for the same consideration per security and on the same terms as were applicable to such issuance by the Company.

 

Section
5.2 Transfer of Common Shares.

 

(a)
Permitted Transfers. (i) Notwithstanding anything to the contrary in this Agreement, the Shareholders may at any time,
without being subject to Section 5.2(b), Transfer their respective Common Shares (x) to any of their Affiliates thereof (the “Permitted
Transferees”), or (y) with the prior consent of the other Parties to this Agreement, or (z) as otherwise permitted
under this Agreement.

 

(ii)
If a Permitted Transferee ceases to be an Affiliate of the Shareholder who Transferred Common Shares to such Permitted Transferee,
the Shares shall automatically revert or otherwise be transferred back to the original Shareholder. The agreement or other instrument
pursuant to which a Shareholder carries out a Permitted Transfer must specifically contain a provision expressly contemplating
the reversion of Shares or unwinding of the Permitted Transfer should the transferee cease to be a Permitted Transferee at any
time after the corresponding Transfer. If according to the applicable law such reversion is not permitted or the transferring
Shareholders does not accept such reversion, then the non-transferring Shareholder of the Company shall be entitled to: (x) acquire
directly or through a subsidiary, the totality of the Shares of the Permitted Transferee that ceased to be an Affiliate, (y) to
request the Company to carry out a capital reduction in order to redeem the Shares of the Permitted Transferee that ceased to
be an Affiliate or (z) a combination of the rights set forth in (x) and (y) of this subsection (ii). The agreement or other instrument
pursuant to which a Shareholder carries out a Permitted Transfer must specifically contain a provision expressly granting such
rights to the non-transferring Shareholder.

 

    	 	 -13-	 

    	 	 	 

    

 

(iii)
Each Shareholder shall previously notify in writing the other Shareholders and the Company of any Permitted Transfer.

 

(iv)
Any attempted Transfer in violation of the terms of this Agreement and the By-laws of the Company shall be deemed null and void
and the Company shall refuse to document or recognize such transfer in the corporate books of the Company.

 

(b)
Right of First Refusal. In the event a Shareholder wishes to sell, dispose of, transfer or assign its Common Shares in
the Company, the other Shareholder(s) shall have the irrevocable right of first refusal (“Right of First Refusal”),
pursuant to the following terms and conditions:

 

(i)
Notice of Offer. In the event a Shareholder, directly or indirectly, at any time, wishes or has the intention to Transfer
any of its Common Shares to a third party such Shareholder must deliver written notice of such intention to the other Shareholder(s)
and to the Chairman of the Board of Directors (the “Notice of Offer”), indicating (i) the number of
Common Shares owned by the Shareholder that are subject to such Transfer (the “Offered Shares”), (ii)
the purchase price (the “Minimum Price”) for such Offered Shares, and (iii) all other material terms
and conditions of the proposed Transfer, including payment terms and the identity of the potential third party purchaser (the
“Third Party Purchaser”) with sufficient detail.

 

(ii)
ROFR Exercise Period. The non-transferring Shareholder(s), within thirty (30) calendar days after the receipt of the Notice
of Offer (the “ROFR Exercise Period”), may choose to either (i) purchase the Offered Shares or (ii)
not respond to the Notice of Offer. In the event a non-transferring Shareholder wishes to purchase the Offered Shares, it must
exercise its Right of First Refusal by written notice (“Notice of Exercise”) given to the transferring
Shareholder of its intent to purchase all, and not less than all, of the Offered Shares on the terms contained in the Notice of
Offer, at the proposed Minimum Price. In the event that several non-transferring Shareholders deliver a Notice of Exercise regarding
their intent to purchase the Offered Shares, the same shall be Transferred by the transferring Shareholder on a pro rata
basis to the non-transferring Shareholders, pursuant to the number of shares they own in capital stock of the Company.

 

    	 	 -14-	 

    	 	 	 

    

 

(iii)
Transfer and ROFR Deposit. The Notice of Exercise shall be accompanied by a non-reimbursable deposit of no less than twenty
percent (20%) of the Minimum Price set forth in the Notice of Offer (the “ROFR Deposit”).

 

(iv)
The Transfer of the Offered Shares shall be made in favor of the non-transferring Shareholder(s) who delivered a Notice of Exercise,
on the same basis set forth in the Notice of Offer, within sixty (60) calendar days after the receipt of the Notice of Exercise.
The remaining portion of the Minimum Price must be paid by the non-transferring Shareholder in immediately available funds at
closing of the Transfer.

 

(v)
If upon delivery of the Notice of Exercise the ROFR Deposit is not made, the Notice of Exercise shall be considered as not delivered
and the transferring Shareholder shall have the right to Transfer the Offered Shares to the Third Party Purchaser under the same
material terms, including price, outlined to the Shareholders in the Notice of Offer. Notwithstanding the foregoing, the transferring
Shareholder has the right to impose a penalty, in the amount of the respective ROFR Deposit, on the non-transferring Shareholder(s)
if the non-transferring Shareholder(s) made the ROFR Deposit but later fail(s) to consummate the purchase of the Offered Shares
pursuant to the terms of this Agreement for reasons attributed to the non-transferring Shareholder(s). In this event,, the non-transferring
Shareholder(s) shall forfeit the applicable ROFR Deposit.

 

For
purposes of the Transfer of Common Shares between Shareholders, the only required representations and warranties shall be those
related to ownership of the Offered Shares and nonexistence of Liens thereupon.

 

(vi)
Termination of ROFR Exercise Period. If upon termination of the ROFR Exercise Period, a non-transferring Shareholder: (i)
fails to timely deliver a Notice of Exercise regarding all of the Offered Shares in accordance with Section 5.2(b), or (ii) having
delivered the Notice of Exercise, does not purchase the Offered Shares pursuant to the terms set forth above, the transferring
Shareholder shall be entitled to enter into a stock purchase agreement (the “Third Party Sale Agreement”)
with the Third Party Purchaser pursuant to which the transferring Shareholder agrees to sell the Offered Shares to such Third
Party Purchaser under the same terms as those described in the Notice of Offer.

 

The
closing of the sale of all of the Offered Shares under this Article Five will occur no later than ninety (90) calendar days after
the day all Shareholders received the Notice of Offer. If the sale is not made within said ninety (90) calendar day term, the
sale process set forth herein must once again be initiated. In the event the Transfer of the Offered Shares requires third party
or Governmental Authority authorization, said ninety (90) calendar day term shall be extended as required by said third party
or Governmental Authority to accept or reject the sale.

 

    	 	 -15-	 

    	 	 	 

    

 

(vii)
Adhesion. In the event the Third Party Purchaser acquires all the Offered Shares owned by a Shareholder in the capital
stock of the Company, in order for said Transfer to be effective, simultaneously to the date on which the Transfer shall become
effective, the Third Party Purchaser must agree in writing to be bound by the terms and conditions set forth in this Agreement
and the By-laws, on the same terms, mutatis mutandis, as the transferring Shareholder was bound thereunder.

 

Any
Transfer that occurs with respect to the Company without compliance with the terms set forth in this Section 5.2 shall
be null and void, and shall not be effective against the Company or the Shareholders of the Company and the Company shall not
record such transfer in the corporate books of the Company. In such event, the Third Party Purchaser may not exercise any rights
pertaining to the Offered Shares.

 

(viii)
Void Assignments. Shareholders agree that any Transfer of Common Shares of the Company executed, directly or indirectly,
through any means, including transfer of Common Shares, partnership interests or similar equities in other companies or rights
regarding such equities, shall be void, and shall not be effective against the Company or the Shareholders, and such Transfer
shall not be enforceable unless such Transfer of Common Shares complies with the provisions set forth in this Article Five.

 

Article
VI

COMPANy
SUBSIDIARIES

 

Section
6.1 Company Subsidiaries. With respect to any subsidiaries incorporated by the Company to directly or indirectly carry
out their business in the Mexican territory or in MALA or ROW; OBMP and Vitel hereby covenant and agree to operate and manage
each such Company ́s subsidiary in a manner consistent with the terms hereof. OBMP and Vitel also agree that such subsidiaries
shall, to the fullest extent permitted under Applicable Law be governed by the same terms and conditions set forth in the Company’s
By-laws, as amended and restated pursuant to Section 7.1 hereof and from time to time.

 

Article
VII

OTHER
AGREEMENTS

 

Section
7.1 Company’s By-laws and Conflict Of Interest.

 

(a)
Company’s By-laws. The Company shall within 5 (five) Business Days as of the date hereof, amend and restated its
By-laws to adopt the form of By-laws attached to this Agreement under Exhibit D.

 

(b)
Conflict of Interests. The Shareholders hereby agree that all of its decisions and actions with respect of the Company
shall be made primarily for the benefit of the Company, and not for their individual benefit.

 

    	 	 -16-	 

    	 	 	 

    

 

To
avoid any conflict of interest, the Shareholders agree:

 

(1)
To notify the Company in writing of any corporate or business ties, employment or other circumstance which could originate a conflict
of interest, within MALA;

 

(2)
To reject any payment or consideration from any third party, in any form, that may affect its ability to make independent decisions
related to the Company;

 

(3)
Not to make or offer any gifts of any kind to third parties, in exchange for services from the Company, except for customary gifts
not exceeding US$100.00 (one hundred and 00/100 Dollars);

 

(4)
Not to perform any activities for personal gain or in favor of third parties which could imply a competing activity within MALA;
and

 

(5)
Conduct their business ethically, in compliance with laws and pursuant to the business judgment rule, and in any case in such
a way as not to adversely affect the reputation of the Company.

 

Further,
the members of the Board of Directors shall be obliged:

 

(1)
To notify the Company in writing of any affiliate relationship, family ties, friendships, employment or other circumstance which
could, originate a conflict of interest within MALA;

 

(2)
To reject any payment or consideration from any third party, in any form, that may affect its ability to make independent decisions
related to the Company;

 

(3)
Not to make or offer any gifts of any kind to third parties, in exchange for services from the Company, except for customary gifts
not exceeding US$100.00 (one hundred and 00/100 Dollars);

 

(4)
Not to perform any activities for personal gain or in favor of third parties which could imply a competing activity, within MALA;
and

 

(5)
Conduct their business ethically, in compliance with laws, and in any case in such a way as not to adversely affect the reputation
of the Company.

 

    	 	 -17-	 

    	 	 	 

    

 

Section
7.2 Patents, Sanitary Registrations and Licenses

 

The
parties hereto agree and acknowledge that ownership to any and all proprietary rights, including the intellectual property and
the technology (present or to be developed), in connection with the Products and the Pipeline Products should be separated as
follows: within the U.S. and ROW the owner shall be OBMP, while in the MALA the owner shall be the Company. Guided by this general
intent, the parties hereto agree as to the following:

 

(a)
Patents. OBMP has obtained and/or has applied to obtain Patents in the U.S. and other countries around the world for the
Products, as applicable. Thus, the parties hereto agree as to the following:

 

(1)
ROW and U.S. Patents. OBMP shall maintain sole ownership of the Patents, including the Base Patents, Derivative Patents
and Other Patents and all existing and future technology in connection with the Products in the U.S. and ROW, where applicable.
The maintenance of the Patents in the U.S. and ROW will be the sole responsibility of OBMP, including the annuity payments, if
any, and other requirements to keep the Patents in the U.S. and ROW in force. OBMP will provide the Company notice of any new
filings or patent application in the U.S. and/or ROW for Derivative Patents and Other Patents no later than 30 days after the
filing date of such patent application, so that the Company may decide if such a patent shall be protected as well in the MALA
countries, within the deadlines established in the Paris Convention (priority rights). Further, any and all new Patent applications
by OBMC filed or applied for under the Patent Cooperation Treaty (PCT) system shall initially designate all MALA countries, to
insure that said patent may be protected in said countries. OBMC shall assist and aid the Company, the Company Affiliates and/or
the designated patent holder when and where necessary to obtain protection of such patents in MALA and to avoid the loss of any
potential Patent rights, as a consequence of allowing the technology to fall into the State of the Art. Any and all new patents
in MALA countries will then have to be assigned or transferred to the Company in terms of paragraph 7(a)(2) hereunder to ensure
its proprietary rights thereto.

 

(2)
MALA Patents. OBMP acknowledges that the use of any Base Patent by the Company within MALA does not constitute patent infringement.
OBMP shall assign all title, right and/or interest to the pending patent in Mexico, listed under number 5 of Exhibit F, as well
as of any other granted patent or pending patent not listed in Exhibit F that OBMP may have rights to within the MALA in favor
of the Company or any Affiliate legal Person, including a Holding Company, or any other Person in which the Shareholders own a
majority portion of the equity, and/or have direct and/or indirect control over the decision making structures of such Person.
OBMC shall also assign a limited title, right and/or interest to any Derivative Patents and/or Other Patents that may arise in
the future to allow the Company to fully, and without restriction, use the technology disclosed in the Derivative Patents and/or
Other Patents and obtain patents on such technology in MALA consistent with the intent set forth in paragraph 7(a)(1) herein above.
The maintenance of any such Patent rights within MALA, if any, will be the sole responsibility of the Company and/or the designated
patent holder, including the annuity payments and other requirements to keep the patents in force in each territory. OBMP will
assist and aid the Company and/or the designated patent holder when and where necessary to avoid the loss of any Patent rights
or potential patent rights.

 

    	 	 -18-	 

    	 	 	 

    

 

(3)
Patent licenses in ROW and the U.S. OBMP shall comply with all applicable ROW and U.S. laws and regulations in connection
with patent licensing and do so at its own discretion. The Parties herein agree that the only limitation to OBMP’s prerogatives
to license the Patents in the U.S. and ROW is the prevention of parallel imports in the MALA of Products manufactured for sale
within the U.S. and ROW under license granted by OBMP. Thus, any and all licenses granted by OBMP in connection with Patents in
the U.S. and in the ROW shall contain specific provisions to prevent and/or stop the sale of the Products into MALA.

 

(4)
Patent licenses MALA. The Company and/or its designated Patent holder shall comply with all applicable laws and regulations
of each specific country or territory for patent licensing, including the arm’s length principle, particularly if the license
is among related parties as it relates to the MALA Patent Rights. The duration of the patent licenses may never exceed the duration
of the patent rights in the specific country. Any and all patent licenses as it relates to the MALA Patent Rights shall contain
specific provisions to prevent and/or stop parallel exports of the patented Products outside MALA.

 

(b)
Trademarks. For the purpose of this agreement “Trademarks” shall mean the distinctive signs ONCBIOMUNE, OVCAVAX
and PROSCAVAX, as well as any logos, artwork or visual or sound elements associated therewith or use in conjunction thereto; and
any other future brand that may be developed or acquired in the future by either OBMP or the Company.

 

OBMP
is currently the title holder of several common law rights to the trademarks and a trademark registration in connection with pharmaceutical
products and medicines, in particular pharmaceutical products and medicines for the treatment of cancer, including but not limited
to the Products, in class 5, as well as of the service marks in connection with the sale and distribution of pharmaceutical products
and medicines, in particular pharmaceutical products and medicines for the treatment of cancer, including but not limited to the
Products, in class 35, both in the U.S., or is in the process of obtaining registrations thereof. Further, OBMP may be in the
process of obtaining substantial rights to the trademarks in MALA through registration or may own trademark registration in MALA.
Thus, the Parties hereto agree as follows:

 

(1)
ROW and U.S. Trademarks.- Any and all trademark rights currently owned by OBMP or obtained in the future by OBMP within
ROW and/or the U.S., whether Federal or State, are and shall remain the sole property of OBMP and/or its successors in business.

 

(2)
MALA Trademarks.- Any and all trademark rights currently owned by OBMP or obtained in the future within the territories
of MALA shall be the sole property of the Company or any Affiliate legal Person, including a holding company, or any other Person
in which the Shareholders own a majority portion of the equity, and/or have direct and/or indirect control over the decision making
structures of such Person. Thus, OBMP shall assign all title, rights and/or interest in connection with the existing registrations
or pending applications, if any, in MALA in favor of the Company or the designated trademark holder. The prosecutions, maintenance
and/or renewal of any existing trademark registrations or pending applications within MALA shall be the sole responsibility of
the Company or of the designated trademark holder. Further, the prosecution or procurement of additional registrations for the
Trademarks and/or trademarks related thereto within MALA, as required, shall be the sole responsibility of the Company or of the
designated trademark holder, acting as applicant thereof. OBMP will assist and aid the Company and/or the designated trademark
holder when and where necessary to avoid the loss of any trademark rights and/or for the procurement of new trademark rights.

 

    	 	 -19-	 

    	 	 	 

    

 

(3)
Trademark licenses in ROW and the U.S. OBMP shall comply with all applicable U.S. and other ROW laws and regulations in
connection with trademark licensing in ROW and the U.S. at its sole discretion. The Parties herein agree that the only limitation
to OBMP’s prerogatives to license the trademarks in the U.S. and ROW is the prevention of parallel imports in the MALA of
Products manufactured for sale within the U.S. and ROW under license granted by OBMP. Thus, any and all licenses granted by OBMP
in connection with trademarks in the U.S. and in the ROW shall contain specific provisions to prevent and/or stop the sale of
the Products into MALA.

 

(4)
Trademark licenses in MALA. The Company and/or its designated trademark holder shall comply with all applicable laws and
regulations for each specific country or territory in MALA for trademark licensing, including the arm’s length principle,
particularly if the license is granted among related parties. The licenses in MALA may include the right to sublicense, as well
as the right to enforce and maintain the trademark rights in every individual country within MALA. The licenses for trademarks
in MALA shall also include the right to co-brand the Products and services with self-owned and developed trademarks and/or service
marks property of the licensee or sublicensee.

 

(c)
Sanitary registration. The Company shall obtain and maintain, if required, any sanitary registrations or permits with any
Governmental Authority, required for the development, manufacture and commercialization of the Products in México or in
any other country in which the Company shall or is entitled to pursue business. The Company will be the preferred Sanitary Registration
holder in each individual country, whenever that is legally possible.

 

Section
7.3 Board of Directors and Officers of the Company on the Closing Date. The Shareholders agree that as of the Closing Date
and until Board members and their corresponding alternates are removed and replaced, and their respective replacements have actually
assumed such position, the Board shall be integrated as follows:

 

	Name	 	Title	 	For
    purposes of Section 3.3. hereof appointed by
	Dr.
    Jonathan Frederick Head	 	Chairman	 	OBMP
	Manuel
    Cosme Odabachian	 	Director
    and Secretary	 	Vitel
	Andrew
    Albert Kucharchuck	 	Director	 	OBMP
	Carlos
    Fernando Alaman Volnie	 	Director	 	Vitel

 

    	 	 -20-	 

    	 	 	 

    

 

(b)
The Shareholders of the Company agree that as of the Closing Date, Dr. Jonathan Frederic Head will be elected as Chief Executive
Officer of the Company, to serve in accordance with the By-laws of the Company and at the discretion of the Board.

 

(c)
The Shareholders of the Company agree that as of the Closing Date or such date thereafter as determined by the Board of Director,
the Board of Directors will designate the Company’s auditors.

 

(d)
The Chairman of the Board shall have an additional casting vote (voto de calidad) in case of a deadlock during a Board
of Directors’ Meeting of the Company.

 

Section
7.4 Dividends. Net profits obtained in each fiscal year may only be distributed to the Shareholders once the audited financial
statements reflecting such net profits are approved at the Shareholders’ Meeting and subject to available cash. The distribution
of profits shall be made only after the losses from prior fiscal years have been absorbed or the capital stock of the Company
is reduced to that effect subject to the dividend policy approved by the Shareholders and in effect.

 

Section
7.5 Funding. The Shareholders shall equally split all expenses related to: (i) the formation of the Company and any other
required corporate amendment required to it, (ii) the planned Phase 2A/2B clinical trial of the product called ProscaVax for prostate
cancer (iii) any other expenses related to the registration of trademarks, intellectual property, and patents in connection with
the Products in MALA and (iv) other expenses related to corporate and drug development of the Company. Investment milestones shall
be defined by the Shareholders.

 

Article
VIII

FINANCIAL
INFORMATION AND AUDITS

 

Section
8.1 Periodic Information. The Chief Financial Officer or
Treasurer shall prepare its financial information, including its annual audited and interim unaudited financial statements pursuant
to general accepted accounting practices, and shall provide the same to the Shareholders at the corporate domicile within the
first fiscal quarter of the following fiscal year.

 

Section
8.2 Visits and Inspection. The Shareholders shall have
access to, at any time as requested, during business hours, upon written notice delivered to the Company, any officer and any
documentation of the Company, including documentation on any of its assets.

 

Section
8.3 Audits. Any of the Shareholders may, at their discretion,
perform an audit of the Company, provided that such audit shall not interrupt the ordinary course of business of the Company,
and the Company and its officers shall adopt all necessary measures to assist the Shareholders and the individuals appointed by
such Shareholders to perform those audits.

 

Section
8.4 Bank Accounts. The Company shall open and maintain
one or more bank accounts for its operations, which shall be opened in the Company’s name and in which all amounts related
to the Project shall be deposited (in the same manner in which such amounts were received, i.e. checks and cash, among others).
Any transaction that exceeds $10,000.00 (ten thousand Dollars) shall require signatures from both the Chairman of the Board and
one other Director.

 

    	 	 -21-	 

    	 	 	 

    

 

Article
IX

MISCELLANEOUS

 

Section
9.1 Headings. The headings in this Agreement are for convenience
of reference only and shall not control or affect the meaning or construction of any provisions hereof.

 

Section
9.2 Entire Agreement. This Agreement constitutes the entire
agreement and understanding of the Parties hereto in respect of the subject matter contained herein, and there are no promises,
representations, warranties, covenants, conditions or undertakings with respect to the subject matter hereof, other than those
expressly set forth or referred to herein. This Agreement supersedes all prior agreements and understandings between the Parties
hereto with respect to the subject matter hereof.

 

Section
9.3 Confidentiality. The Parties agree to maintain the
confidentiality of the Information (as defined below), except that Information may be disclosed (i) to its shareholders, directors,
officers, employees and agents, including accountants, legal counsel and other advisors (it being understood that the Persons
to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information
confidential), (ii) to the extent requested by any regulatory authority, (iii) to the extent required by applicable laws or regulations
or by any subpoena or similar legal process, (iv) to any other Party to this Agreement, or (v) to the extent such Information
becomes publicly available other than as a result of a breach of this paragraph. For the purposes of this paragraph, “Information”
means all information received from by any Party from the other Parties.

 

Section
9.4 Further Actions; Cooperation. Each of the Shareholders
agrees to use its reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, and to assist
and cooperate with the other parties in doing, all things necessary, proper or advisable to give effect to the transactions contemplated
by this Agreement, including but not limited to the OBMP ́s obligations under Section 7 hereof.

 

Section
9.5 Notices. All notices, requests, consents and other
communications hereunder to any Party shall be deemed to be sufficient if contained in a written instrument delivered in person
or sent by facsimile, nationally recognized overnight courier or first class registered or certified mail, return receipt requested,
postage prepaid, and addressed to such Party at the address set forth below or such other address as may hereafter be designated
on the signature pages of this Agreement or in writing by such Party to the other Parties:

 

    	 	 -22-	 

    	 	 	 

    

 

	 	if to the Company:

         

        Oncbiomune México, S.A. de C.V. 

        Manuel Cosme Odabachian

        Monte Pelvoux 130 Piso 3 

        Lomas de Chapultepec

        Mexico City, Mexico

        C.P. 110000

        Telephone: + 52 55 5202 5854

        Email: mcosm@vitelpharma.com

         

	 	if to the OBMP:

         

        OncBioMune Pharmaceuticals Inc.

        Jonathan F. Head, PhD.

        Chief Executive Officer, Chairman

        11441 Industriplex Blvd., Suite 190

        Baton Rouge, LA 70809

        Phone: 1-225-227-2384

        Fax: 1-225-227-2957

        E-mail: jhead@oncbiomune.com

	 	 

        if to Vitel:

         

	 	Vitel Laboratorios, S.A. de C.V.

        Manuel Cosme Odabachian

        Chief Executive Officer, Chairman

        Monte Pelvoux 130 Piso 3

        Lomas de Chapultepec

        Mexico City, Mexico

        C.P. 110000

        Telephone: + 52 55 5202 5854

        Email: mcosm@vitelpharma.com

 

All
such notices, requests, consents and other communications shall be deemed to have been given or made if and when received (including
by overnight courier) by the Parties at the above addresses or sent by electronic transmission, with confirmation received, to
the facsimile numbers specified above (or at such other address or telecopy number for a Party as shall be specified by like notice).
Any notice delivered by any Party hereto to any other Party hereto shall also be delivered to each other Party hereto simultaneously
with delivery to the first Party receiving such notice.

 

Section
9.6 Applicable Law. The laws of the State of Nevada shall govern the interpretation, validity and performance of
the terms of this Agreement, without regard to conflicts of law doctrines.

 

    	 	 -23-	 

    	 	 	 

    

 

Section
9.7 Severability. The invalidity, illegality or unenforceability
of one or more of the provisions of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability
of the remainder of this Agreement, including any such provisions, in any other jurisdiction, it being intended that all rights
and obligations of the Parties hereunder shall be enforceable to the fullest extent permitted by law.

 

Section
9.8 Successors and Assigns. Except as otherwise provided
herein, all the terms and provisions of this Agreement shall be binding upon, shall inure to the benefit of and shall be enforceable
by the respective successors and permitted assigns of the Parties hereto. No Shareholder may assign any of its rights hereunder
to any Person other than a Permitted Transferee to which Common Shares are transferred by a Shareholder and that has complied
in all respects with the requirements of this Agreement. Each such Permitted Transferee of any Shareholder shall be subject to
all of the terms of this Agreement, and by taking and holding such shares and executing the adhesion agreement described in Section
5.2.(b)(vii) such Person shall be entitled to receive the benefits of and be conclusively deemed to have agreed to be bound by
and to comply with all of the terms and provisions of this Agreement.

 

Section
9.9 Amendments. This Agreement may not be amended, modified
or supplemented unless such amendment, modification or supplement is in writing and signed by each of the Shareholders and the
Company.

 

Section
9.10 Waiver. The failure of a Party hereto at any time
or times to require performance of any provision hereof shall in no manner affect its right at a later time to enforce the same.
No waiver by a Party of any condition or of any breach of any term, covenant, representation or warranty contained in this Agreement
shall be effective unless in writing, signed by the Party against whom the waiver is to be effective, and no waiver in any one
or more instances shall be deemed to be a further or continuing waiver of any such condition or breach in other instances or a
waiver of any other condition or breach of any other term, covenant, representation or warranty.

 

Section
9.11 Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same Agreement.

 

Section
9.12 Injunctive Relief. Each Party hereto acknowledges
and agrees that a violation of any of the terms of this Agreement will cause the other Parties irreparable injury for which an
adequate remedy at law is not available. Therefore, each Party shall be entitled to an injunction, restraining order, specific
performance or other equitable relief from any court of competent jurisdiction, restraining any Party from committing any violations
of the provisions of this Agreement.

 

Section
9.13 SUBMISSION TO JURISDICTION. ANY LEGAL ACTION OR PROCEEDING
WITH RESPECT TO THIS AGREEMENT AND ANY ACTION FOR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF MAY BE BROUGHT IN THE COURTS
OF THE STATE OF NEVADA AND, BY EXECUTION AND DELIVERY OF THIS AGREEMENT, EACH PARTY HERETO HEREBY ACCEPTS FOR ITSELF AND IN RESPECT
OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, THE EXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND THE APPELLATE COURTS THEREOF.
EACH PARTY HERETO IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OUT OF ANY OF THE AFOREMENTIONED COURTS IN ANY SUCH ACTION OR
PROCEEDING BY THE MAILING OF COPIES THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, RETURN RECEIPT REQUESTED, TO SUCH
PARTY AT THE ADDRESS FOR NOTICES SET FORTH HEREIN. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY OBJECTION WHICH IT MAY NOW
OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY OF THE AFORESAID ACTIONS OR PROCEEDINGS ARISING OUT OF OR IN CONNECTION WITH THIS
AGREEMENT BROUGHT IN THE COURTS REFERRED TO ABOVE AND HEREBY FURTHER IRREVOCABLY WAIVES AND AGREES NOT TO PLEAD OR CLAIM IN ANY
SUCH COURT THAT ANY SUCH ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

 

    	 	 -24-	 

    	 	 	 

    

 

Section
9.14 Recapitalizations, Exchanges, Etc. Affecting the Common Shares; New Issuances.
The provisions of this Agreement shall apply to the full extent set forth herein with respect to Company Securities and to any
and all equity or debt securities of the Company or any successor or assign of the Company (whether by merger, amalgamation, consolidation,
sale of assets, or otherwise) which may be issued in respect of, in exchange for or in substitution of, such Company Securities,
and shall be appropriately adjusted for any share dividends, splits, reverse splits, combinations, reclassifications, recapitalizations,
reorganizations and the like occurring after the date hereof.

 

Section
9.15 Term. This Agreement will be effective as of the date
hereof and, except as otherwise set forth herein, will continue in effect thereafter until terminated upon the mutual consent
of all of the Parties hereto.

 

Section
9.16 By-laws. To the extent this Agreement is in conflict,
contravenes or violates any provision of the By-Laws, the Company and the Shareholders shall, to the extent possible, use their
reasonable best efforts to cause the By-laws to be amended to reflect the terms of this Agreement.

 

Section
9.17 Preferential Rights for New Projects. Each Shareholder
shall promptly notify the other Shareholder and the Company of any business opportunities in ROW with regard to the Products and/or
the Patents, Base Patents and Derivative Patents (the “ROW Opportunity”). In the event that the Company decides not
to participate in such new business opportunity but one or more of the Shareholders wish to participate directly, the Shareholder
who originally procured the ROW Opportunity (the “Original Shareholder”) shall make its best efforts to offer the
remaining Shareholders of the Company the right to participate in the ROW Opportunity on the same terms as the other Shareholder.
A Shareholder who is presented with an ROW Opportunity shall have a period of thirty (30) days in which to decide to participate.
In the event the parties to the ROW Opportunity are unable to reach an agreement to consummate the transaction contemplated by
the ROW Opportunity within thirty (30) days, the Original Shareholder shall be free to pursue the ROW Opportunity without the
remaining Shareholders of the Company.

 

    	 	 -25-	 

    	 	 	 

    

 

[Remainder
of page left blank intentionally]

 

[Signature
pages follow]

 

    	 	 -26-	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered by their respective officers thereunto
duly as of the date first above written.

 

	 	ONCBIOMUNE
    MÉXICO, S.A. DE C.V.
	 	 	 
	 	By:	/s/
    Manuel Cosme Odabachian
	 	Name:
    	Manuel
    Cosme Odabachian
	 	Title:
    	Authorized
    Signatory
	 	 	 
	 	ONCBIOMUNE
    PHARMACEUTICAL INC.
	 	 	 
	 	By:	/s/
    Jonathan Frederic Head
	 	Name:	Jonathan
    Frederic Head, PhD.
	 	Title:	Authorized
    Signatory
	 	 	 
	 	VITEL
    LABORATORIOS, S.A. DE C.V.
	 	 	 
	 	By:	/s/
    Jonathan Frederic Head
	 	Name:	Manuel
    Cosme Odabachian
	 	Title:	Authorized
    Signatory

 

[Shareholders
Agreement Signature Page]

 

    	 	 -27-	 

    	 	 	 

    

 

Appendix
A

 

List
of the Countries

 

	 	1	Mexico
	 	2	Belize
	 	3	Costa
    Rica
	 	4	El
    Salvador
	 	5	Guatemala
	 	6	Honduras
	 	7	Nicaragua
	 	8	Panama
	 	9	Antigua
    y Barbuda
	 	10	Bahamas
	 	11	Barbados
	 	12	Cuba
	 	13	Dominican
    Republic
	 	14	Granada
	 	15	Haiti
	 	16	Jamaica
	 	17	San
    Cristobal y Nieves
	 	18	San
    Vicente
	 	19	Santa
    Lucia
	 	20	Trinidad
    & Tobago
	 	21	Bolivia
	 	22	Colombia
	 	23	Ecuador
	 	24	Peru
	 	25	Argentina
	 	26	Brazil
	 	27	Chile
	 	28	Ecuador
	 	29	Guyana
    Francesa
	 	30	Guayana
	 	31	Paraguay
	 	32	Surinam
	 	33	Uruguay
	 	34	Venezuela

 

    	 	 -28-	 

    	 	 	 

    

 

Exhibit
A

 

Memorandum
of Understanding

 

    	 		 

    	 		 

    

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

  

 

    	 

    	 	 	 

    

 

Exhibit
B

 

Incorporation
deed Oncbiomune México, S.A. de C.V.

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

Exhibit
C

 

Pipeline
Products

 

	1.	Ovcavax®
    Ovarian Cancer
	 	 
	2.	PA-OBC
    – Breast Cancer
	 	 
	3.	PGT-OBM
    – Renal Cancer
	 	 
	4.	Any
    other product under development, developed to be developed by OBMP and/or by Dr. Head in collaboration, under contract or
    under any other type of business relationship with OBMP or with any OBMP related Person.

 

    	 

    	 	 	 

    

 

Exhibit
D

 

Products

 

	1.	Proscavax®
    Prostate Cancer;
	 	 
	2.	Pipeline
    Products; and
	 	 
	3.	OBMP
    Vaccine Technology, OBMP cancer technologies for the treatment of prostate, ovarian and various other types of cancer and
    any other technology for medical treatment, drug or medical treatment owned by OBMP or by any OBMP related Person.

 

    	 

    	 	 	 

    

 

Exhibit
E

 

Form
of By-laws

 

    	 

    	 	 	 

    

  

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

  

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

  

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

 

    	 

    	 	 	 

    

 

Exhibit
F

 

Patents

 

	1.	Vaccination
    of Cancer Patients Using Tumor-Associated Antigens Mixed with Interleukin-2 And Granulocyte-Macrophage Colony Stimulating
    Factor. U.S. Patent No. 5,478,556. Robert L. Elliott and Jonathan F. Head. Expired 2/28/14.
	 	 
	2.	Composition
    and Method for Treating Cancer. (Protein Therapeutic Cancer Vaccine) U.S. Patent Application No. 13/005,993; Continuation
    Application No. 14/137,060; U.S. Patent No. 8,647,627. Jonathan F. Head and Robert L. Elliott. Expires 1/13/31. Patent Ukraine
    No. A 2013 09855. Patent People’s Republic of China (PRC) No. 201080005114.4.
	 	 
	3.	Immunological
    Method for Treating Cancer (Protein Therapeutic Cancer Vaccine) U.S. Patent Application No. 14/137,060; U.S. Patent No. 9,211,322.
    Jonathan F. Head and Robert L. Elliott. Expires 1/13/31.
	 	 
	4.	Taxane-
    and Taxoid-Protein Compositions. U.S. Provisional Patent Application No. 61/301006, U.S. Patent Application No. 13/017,173.
    U.S. Patent No. 9,333,189 B2. Jonathan F. Head and Robert L. Elliott. Expires 1/31/31.
	 	 
	5.	Composition
    and Method for Treating Cancer, Mexican Patent Application No. MX/a/2013/008188 dated 01/09/2012, Docket No. 24412MX01.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]